CONFIDENTIAL  
The information contained in this document is regarded as confidential, and may not be disclosed to 
another party unless such disclosure is required to initiate the study, to conduct study -related activities, or 
to comply with national, state, or local laws and regulations.  Written authorization from the coordinating 
site and sponsor is required for disclosure otherwise.  
PT-PhI-II v05.22.12 AVeRT: Anti-PD-1 monoclonal antibody (nivolumab) in combination with DC Vaccines for the Treatment 
of Recurrent  Grade III and Grade IV Brain T umors  
 
     
 
  
 Sponsor : PI – Duke Cancer Institute    
 Funding Source:  BMS and Departmental Funds    
 Protocol Source:  PI - Duke Cancer Institute    
 Duke IRB#:  Pro000 [ZIP_CODE]    
 IND#:  
 [ZIP_CODE]   
Principal Investigator  
[INVESTIGATOR_34480] , M.D., 
Ph.D.  
katherine. peters  @duke.edu 
  Sub-Investigator(s)  
Annick Desjardins, M.D.  
[EMAIL_562]  
 Henry Friedman, M.D.   
[EMAIL_563]  
 Darell Bigner, M.D.  
[EMAIL_564]  
 Dina Randazzo, D.O.  
[EMAIL_3543]  
 John Sampson, M.D., Ph.D.  
[EMAIL_565]  
 Gary Archer, Ph.D.  
[EMAIL_574]  
 Elizabeth Reap, Ph.D.  
[EMAIL_567]  
 Luis Sanchez -Perez, Ph.D.  
luis.sanchez -[EMAIL_3544]  
 Peter Fecci, M.D., Ph.D.  
[EMAIL_568]  Statistician  
James E. Herndon II, Ph.D.  
[EMAIL_571]  
 Lead Study Coordinator  
Stevie Threatt , C.R.C.  
[EMAIL_3545]  
 Regulatory Coordinator  
Rachel Hesler, Ph.D.  
[EMAIL_573]  
 Data Manager  
Eric Lipp  
[EMAIL_575]  
   
Original version:  04/02 /2015   
Amended version 1:  
BMS Modification 
Requests  06/09/2015   
Amended version 2: 
PRTBTC PRC Modification 
Requests  07/24/2015   

Duke Cancer Institute  CONFIDENTIAL  Page 2 
 Amended version 3: 
CPC Modifications 
and PI -initiated 
corrections  08/24/2015  .Added abbreviation (Section   4); Removed research summary 
(Section   5); Updated study schema (Section 6 ); Added more 
background on nivolumab (Section 7 ); Moved randomization 
(Sections 9 , 12, 15); Moved surgery (Sections 9 , 12); Removed 
specific Td manufacturer (Sections 9, 10, 12); Corrected dose of 
Td/Saline for pre- conditioning (Sections 9, 12); Corrected cell 
concentration error (Section 10); Corrected name [CONTACT_179513] (Section 10 ); Removed specific research nurse 
name (Section 10); Updated Tests & Procedures Table (Section 
12); Corrected # of vaccines for primary analysis (Section 15). 
Amended version 4: 
CPC Modifications 
Request  9/8/2015  Clarified rationale for surgery following nivo lumab ± DC vaccine 
and subjects will be removed if surgery must be performed prior 
to plan (Sections 7, 9 and 12). 
Amended version 5: 
FDA Modification 
Requests  9/16/2015  Clinical benefit in Section 12.2.1  is clarified; tolerating study drug 
in same section also clarified; Time point as listed in the PRTBTC 
Imagi ng SOP is clarified in Section 18.3. 
Amended version 6: 
PI [INVESTIGATOR_179437]  1/20/2016  Included Apheresis blood work prior to each leukapheresis 
(Section 12); updated the blood work drawn prior to leukapheresis 
and each inf usion of nivolumab (Section 12), corrected the total 
number of vaccines required for replacement of patients for 
primary endpoint evaluation (Section 15.7); and updated the 
documents in the appendices by [CONTACT_179473] (Section 18). 
Amended vers ion 7: 
PI [INVESTIGATOR_179437]  2/4/2016  Use of antihistamines before, during and following vaccine 
`administration recommendation (Section 12.7.3).  
Amended versio n 8: 
PI [INVESTIGATOR_179438]  5/12/2016  Overall formatting change to meet FDA standards for electronic 
submission (entire document); Changed Primary Study Coordinator (
Cover Page); Removed reference to “alone” from 
Group 2 description since giving nivolumab alone is done prior to randomization (Sections 7.3 & 9.1.6
); Clarified blood draws 
(immune monitoring, and pre- nivo) timing, volume, and tubes , and  
removed CCL3 blood assessments  (Sections  6, 8, 9.1, 12.1, 12.2, 
12.7.5 & 15.6); Clarified subjects whose cells fail to qualify will not 
undergo repeat leukapheresis (Section 9.1); Described how Td 
booster will be administered on all enrolled subjects , removed 
saline injections during Td pre- conditioning (Sections 9.1,12.2); 
Changed timing of study treatments to allow more approximation and flexibility (Section 
9.1, 9.1.4, & 15); Changed listing [CONTACT_179516] to simply  Duke Neurosurgeon (Sections 9.1 & 12.2); 
Updated AE and SAE collection to starting at time of consent through to 30 days after study ends, and includes leukapheresis 
(Sections 
9.1.3, 9.1.4, 12 .6.2, 13 .1, & 13.2.1); Added language 
regarding a deviation log for non- reportable events for missed 
appointments (Section 9.1.4); Clarified that research team will 
document concomitant medications, not just study coordinator 
(Section 9.1.5); Added more language on nivolumab infusion and 
timing (Section 9.2); Updated location of leukapheresis (Section 
10.1); Cla rified eligibility criteria (Section 11 );  Increased 
dexamethasone from 2 mg/day to 4 mg/day (Section 11.2); Updated the Schedule of Events table(s) (Section 
12); Removed 
WHO Performance Status (Sections 12.1 & 18.6); Simplified 
description of standard of care MRI (Sections 12.1 & 12.2.1); 
Removed references to a medical monitor (Sections 12.2.2 & 
12.2.3); Changed nivolumab dose interruption timing from >6 
weeks to >8 weeks (Section 12.2.2); Removed steroid usage as a 
Duke Cancer Institute  CONFIDENTIAL  Page 3 
 criterion for early withdrawal and moved to own section (Sections 
12.6.1 & 12.7.4); Added description of vital sign monitoring with 
nivolumab and vaccine administrations (Section 12.7.2); Changed 
the wording from “bi -weekly” to ev ery other week (QOW) 
(Sections 4, 6, and 15 ); Clarified that TUMS are given three times 
a day instead of “with meals” (Section 12.2); Updated consenting 
by [CONTACT_976] [INVESTIGATOR_179439] (Section 16.3); and fixed minor edits 
and formatting errors (throughout).  
Amended version 9: 
PI [INVESTIGATOR_179437]  8/5/2016  Use of b evacizumab  in subjects that develop inflammation was 
added (Section 9.1.6);   Use of Antihistamines (Section 9.1.4) and 
Use of Corticosteroids (Section  9.1.5 ) were moved from Study 
Assessments (Section  12.7) to Study Design (Section 9.1);  
added definition of WBRT to the List of Abbreviations ; changed 
Primary Regulatory Coordinator to Rachel Hesler; clarification of 
the timing of MRIs and tests and procedures at Nivolumab infusion #1 (Section 12 ); Removed reference to BMS Guidelines 
in appendices in inclusion criteria (Section 11.1
) and fixed minor 
formatting errors (throughout).  
Amended version 
10: PI [INVESTIGATOR_179438]  8/29/2016  Due to  a change in the quality control timeline,  the vaccine 
schedule for Group II subjects  was changed to 3 vaccines prior to 
surgery and 5 vaccines after surgery, keepi[INVESTIGATOR_179440] 8 ( Section 
6, Section 9.1 , Section  12, Section 15); 
Changes were made to Group I vaccine timeline to keep 
consistent ( Section 6, Section 9.1, Section 12); As a result  of 
these changes  to the vaccine timeline, the immune monitoring 
timeline was updated (Section 6 , Section 9.1 , Section 12 ) and the 
primary safety analyses will now focus on all subjects who 
complete at least  3, not 4,  vaccinations  or terminate early due to 
unacceptable toxicity  (Section 9.1, Se ction 15 ); Clarified that 
Nivolumab will be infused over 30- 60 minutes (Section 9.2); 
Clarified that the surgery is for de- bulking purposes (Section  7.3); 
fixed minor formatting errors (throughout).  
Amended version 
11: PI [INVESTIGATOR_179438]  02/13/2017 At leukapheresis #2, subjects (group 1 and group 2) do not need 
to have a physical exam,  neuro exam, KPS, O2 saturation 
(Section  12). Subjects will continue to receive these exams at the 
Nivolumab infusion after leukapheresis #2 (1 day  to 2 weeks 
later) ; Corrected Table [ADDRESS_211071] 3 (not 4) vaccinations will be included in safety analysis (Section 15.7); For subjects whose first leukapheresis yields 8 or more vaccines, the duration of the second 
leukapheresis can be 2 hours instead of 4 hours (Section 12.2) ; 
Complications following resection added to definition of 
unacceptable toxicity (Section 9.1);  Vital signs will be taken right 
after injection of DC vaccine, not 30- [ADDRESS_211072] vaccine 
(Section  12.7.2, Section 12);  In the Criteria for Early Withdrawal 
section (Section 12.6. 1), correction of reference to section 
defining unacceptable toxicity ( Section 9.1.1) instead of  
nivolumab discontinuation criteria ( Section 12.2.2) ; added that a 
subject can continue on one study drug if the other study drug is discontinued due to unacceptable toxicity; Removed restatement of the definition of unacceptable toxicity  and instead referred to 
definition in Section 9.1.1 (Section 15.4.1
);  Correction of 
reference #112 (Section 17) 
Amended version 12  03/15/2017  PI [INVESTIGATOR_115042] (title page and Section 13.2.1 ) 
   
Pro00065241:  AVERT  
Version: [ADDRESS_211073] OF ABBREVIATIONS  .................................................................................................................. 8  
5 PROTOCOL SYNOPSIS AND RESEARCH SUMMARY ................................................................... 11 
6 STUDY SCHEMA  ............................................................................................................................... 12 
7 BACKGROUND AND SIGNIFICANCE  .............................................................................................. 13 
7.1 Study Disease  ............................................................................................................................. 13 
7.2 Study Agent  ................................................................................................................................. 13 
7.2.1  Nivolu mab ........................................................................................................................... 13 
7.2.2  DC Vaccine  ......................................................................................................................... 14 
7.2.3  Tetanus -Diphtheria Toxoid (Td)  .......................................................................................... 15 
7.2.4  Pre-Clinical Experience  ....................................................................................................... 16 
7.2.5  Clinical Experience  .............................................................................................................. 18 
7.3 Study Purpose/Rationale  ............................................................................................................ 20 
8 OBJECTIVES AND ENDPOINTS  ...................................................................................................... 22 
9 INVESTIGATIONAL PLAN  ................................................................................................................. 22 
9.1 Study Design  ............................................................................................................................... 22 
9.1.1  Definition of Unacceptable Toxicity  ..................................................................................... 24 
9.1.2  Dose Modification  ................................................................................................................ 24 
9.1.3 Safety Considerations  ......................................................................................................... 24 
9.1.4  Use of Antihistamines  ......................................................................................................... 24 
9.1.5  Use of Corticosteroids  ......................................................................................................... 25 
9.1.6  Use of Bevacizumab ........................................................................................................... 25 
9.1.7 Missed Doses  ...................................................................................................................... 25 
9.1.8  Concomitant Medications  .................................................................................................... 25 
9.1.9  Randomization  .................................................................................................................... 25 
9.2 Rationale for Selection of Dose, Regimen, and Treatment Duration  .......................................... 25 
9.3 Rationale for Correlative Studies  ................................................................................................ 26 
9.4 Definition of Evaluable Subjects, On Study, and End of Study ................................................... 26 
9.5 Early Study Termination  .............................................................................................................. 26 
10 STUDY DRUG  .................................................................................................................................... 26 
10.1  Names, Classification, and Mechanism of Action  ....................................................................... 26 
10.2  Packaging and Labeling  .............................................................................................................. 28 
10.3  Supply, Receipt, and Storage  ..................................................................................................... 28 
10.4  Dispensing and Preparation ........................................................................................................ 28 
10.5  Compliance and Accountability  ................................................................................................... 28 
Pro00065241:  AVERT  
Version: [ADDRESS_211074](s)  .................................................................................................... 38 
12.6.1  Criteria for Early Withdrawal  ............................................................................................... 38 
12.6.2  Follow -up Requirements for Early Withdrawal  .................................................................... 38 
12.6.3  Replacement of Early Withdrawal(s)  ................................................................................... 38 
12.7  Study Assessments  ..................................................................................................................... 38 
12.7.1  Medical History  .................................................................................................................... 38 
12.7.2  Physical Exam  ..................................................................................................................... 38 
12.7.3  Immunologic Assessments  ................................................................................................. 39 
12.7.4  Correlative Assessments  .................................................................................................... 39 
13 SAFETY MONITORING AND REPORTING  ...................................................................................... 39 
13.1  Adverse Events  ........................................................................................................................... 39 
13.1.1  Reporting of AEs  ................................................................................................................. 40 
13.2  Serious Adverse Events  .............................................................................................................. 40 
13.2.1  Reporting of SAEs  ............................................................................................................... 40 
13.3  Safety Oversight Committee (SOC)  ............................................................................................ [ADDRESS_211075] (DSMB)  .................................................................. 41 
14 QUALITY CONTROL AND QUALITY ASSURANCE  ......................................................................... 42 
14.1  Monitoring  .................................................................................................................................... 42 
14.2  Audits  .......................................................................................................................................... 42 
14.3  Data Management and Processing  ............................................................................................. 42 
14.3.1  Study Documentation  .......................................................................................................... 42 
14.3.2  Case Report Forms (CRFs)  ................................................................................................ 43 
14.3.3  Data Management Procedures and Data Verification ......................................................... 43 
14.3.4  Coding  ................................................................................................................................. 43 
14.3.5  Study C losure  ...................................................................................................................... 43 
15 STATISTICAL METHODS AND DATA ANALYSIS  ............................................................................ 45 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 6 
 15.1  Analysis Sets  ............................................................................................................................... 45 
15.2  Patie nt Demographics and Other Baseline Characteristics  ........................................................ 45 
15.3  Treatments  .................................................................................................................................. 45 
15.4  Primary Objective  ........................................................................................................................ 45 
15.4.1  Variable  ............................................................................................................................... 45 
15.4.2  Statistical Hypothesis, Model, and Method of Analysis  ....................................................... 46 
15.4.3  Handling of Missing Values, Censoring, and Discontinuations  ........................................... 46 
15.5  Secondary Objective  ................................................................................................................... 46 
15.6  Exploratory Objectives  ................................................................................................................ 47 
15.6.1  Exploratory Objective #1:  Immunologic Response to pp65  ............................................... 47 
15.6.2  Exploratory Objectives #2: T -cell Costimulatory Markers  ................................................... 47 
15.6.3  Exploratory Objectives #3: Cytokines and Other Soluble Factors  ...................................... 47 
15.6.4  Exploratory Objectives #4: Gene Expression  ..................................................................... 47 
15.6.5  Exploratory Objectives #5: Epi[INVESTIGATOR_179441]  ................................................................... [ADDRESS_211076]  ....................................................................................................................... 51 
16.10  Registration Procedure  ........................................................................................................... 52 
17 REFERENCES  ................................................................................................................................... 53 
18 APPENDICES  .................................................................................................................................... 60 
18.1  Nivolumab Investigator Brochure(s)  ............................................................................................ 60 
18.2  I-O Safety Algorithms  .................................................................................................................. 61 
18.3  PRTBTC Imaging SOP  ............................................................................................................... 62 
18.4  CTRAF  ........................................................................................................................................ 63 
18.5  MMSE  .......................................................................................................................................... 64 
18.6  PRTBTC DSMBplus Charter  ....................................................................................................... 65 
 
  
Pro00065241:  AVERT  
Version: [ADDRESS_211077] OF TABLES  
Table 1: Objectives and Endpoints  ............................................................................................................. 22 
Table 2. Screening and On -Study Tests and Procedures  .......................................................................... 31 
Table 3. Conditions for Temporary Accrual Suspension ............................................................................ 48 
Table 4. Probability of Accrual Suspension as a Function of the True Unacceptable Toxicity Rate  .......... 48 
 
  
Pro00065241:  AVERT  
Version: [ADDRESS_211078] Aspartate Aminotransferase  
AT Ambient Temperature  
AUC  Area Under the Curve  
β-HCG  Beta-Human Chorionic Gonadotropin  
BMS  Bristol -Myers Squibb  
BMT  Bone Marrow Transplant  
BTSC  Brain Tumor Stem Cells  
Ca++ Calcium  
CCL3  C-C motif Chemokine Ligand 3  
cDNA  Complimentary Deoxyribonucleic Acid  
CFA Complete Freund’s Adjuvant  
CFC Cytokine Flow Cytometry  
CLIA  Clinical Laboratory Improvement Act  
CLN Cervical lymph Nodes  
Cmax  Maximum Concentration of Drug in Plasma or Serum  
CMP  Comprehensive Metabolic Panel  
CMV  Cytomegalovirus  
CNC  Clinical Neurologic Change  
CNS  Central Nervous System  
Con-A Concanavalin A  
CPC  Cancer Protocol Committee  
CRFs  Case Report Forms  
CT Computed Tomography  
CTL Cytotoxic T -Lymphocyte  
CTQA  Clinical Trials Quality Assurance  
DAR  Drug Accountability Record  
DC Dendritic Cell  
DCI Duke Cancer Institute  
DILI Drug Induced Liver Injury  
DLT Dose Limiting Toxicity  
DNA  Deoxyribonucleic Acid  
DSMB  Data Safety and Monitoring Board  
DSMP  Data Safety and Monitoring Plan  
DTH Delayed -type Hypersensitivity  
DUMC  Duke University Medical Center  
EAE Experimental Autoimmune Encephalomyelitis  
EBRT  External Beam Radiation Therapy  
ELISA  Enzyme -Linked ImmunoSorbent Assay  
ELISPOT  Enzyme -linked Immunospot  
EGFR  Epi[INVESTIGATOR_179442] -KLH EGFRvIII conjugated to Keyhole Limpet Hemocyanin  
FACS  Fluorescence Activated Cell Sorting  
FFPE  Formalin -Fixed, Paraffin -Embedded  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 9 
 FDA Federal Drug Administration  
FEV Forced Expi[INVESTIGATOR_179443]-CSF Granulocyte Macrophage Colony Stimulating Factor  
HAMA  Human Anti -Murine Antibody  
H&E Hematoxylin and Eosin  
HIV Human Immunodeficiency Virus  
HLA Human Leukocyte Antigen  
HMO  Health Maintenance Organization  
I.C. Intracerebral  
ICS Intracellular Cytokine Staining  
I.D. Intradermal  
IFN-γ Interferon -gamma  
IgG Immunoglobulin G  
IgM Immunoglobulin M  
IHC Immunohistochemistry  
IL-[ADDRESS_211079]  
ISH In Situ  Hybridization  
I.V. Intravenous  
KLH Keyhole Limpet Hemocyanin  
KPS Karnofsky Performance Status  
LAMP  Lysosomal -associated Membrane Protein  
Lf  Flocculation unit  
MAb Monoclonal Antibody  
MG Malignant Glioma  
MGMT  Methylguanine Methyltransferase  
MHC  Major Histocompatibility Complex  
mL MilliLiter  
MLE Maximum Likelihood Estimator  
MMSE  Mini-Mental Status Examination  
MRI Magnetic Resonance Imaging  
mRNA  Messenger Ribonucleic Acid  
MTD  Maximally Tolerated Dose  
NA Non-adherent  
NCI CTC  National Cancer Institute Common Toxicity Criteria  
ng NanoGram  
NIH National Institutes of Health  
NK Natural Killer  
ORR  Overall Response Rate  
OS Overall Survival  
OVA  Ovalbumin  
PBLs  Peripheral Blood Lymphocytes  
PBMC  Peripheral Blood Mononuclear Cells  
PBS Phosphate Buffered Saline  
PCR  Polymerase Chain Reactions  
PD Progressive Disease  
PHA Phytohemagglutinin  
PFS Progression Free Survival  
PI [INVESTIGATOR_179444]00065241:  AVERT  
Version: [ADDRESS_211080] of Care; Safety Oversight Committee  
TAA Tumor -Associated Antigens  
TCR T cell Receptor  
TD Tetanus -Diphtheria  
TGF-β Transforming Growth Factor -β 
TH2 T helper type [ADDRESS_211081] Upper Limit of Normal  
VDLNs  Vaccine -site Draining Lymph Nodes  
WBI Whole Body Irradiation  
WBRT  Whole Brain Radiation Therapy  
XRT External Radiation Therapy  
 
  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 11  
 5 PROTOCOL  SYNOPSIS AND RESEARCH SUMMARY 
Please see eIRB for separate document uploaded in Section 6.  
  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 12  
 6 STUDY SCHEMA 
 
 
Figure 1. Study Schema  
 
 
  

Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 13  
  
7 BACKGROUND AND SIGNIFICANCE  
7.1 Study Disease 
 
Malignant primary brain tumors are more common than Hodgkin’s disease and account for more human deaths than melanoma or than cancer of the bladder or kidney. Despi[INVESTIGATOR_179445], computer -guided 
tumor resection, high- dose external beam RT or brachytherapy, and multi -mechanistic chemotherapy 
delivered at toxic doses, most patients with malignant primary brain tumors live <15 months from the time of diagnosis, and patients with recurrent tumors usually survive <12 weeks [1-6]. The estimated cost of 
treatment for each patient with a malignant brain tumor is between $30,[ADDRESS_211082] expensive medical therapy per quality -adjusted life-y ear saved currently provided 
in the [LOCATION_002] [7, 8]. Moreover, the non- specific nature of conventional therapy for brain tumors 
often results in incapacitating damage to surrounding normal brain and systemic tissues [9, 10]. Thus, in 
order to be more effective, therapeutic strategies will have to precisely target tumor cells while minimizing 
collateral damage to neighboring eloquent cerebral cortex. The rationale for employing the immune 
system to target brain tumors is based on the premise that the inherent biologic specificity of immunologic reactivity could meet the clear need for more specific and precise therapy.  
7.2 Study Agent  
7.2.1  Nivolumab  
Programmed cell death 1 (PD -1) is a key immune receptor expressed by [CONTACT_93247] T cells that mediates 
immunosuppression.  Blockade of PD -1 may help overcome immune resistance. Nivolumab is a fully 
human monoclonal immunoglobulin (Ig) G4 antibody that binds to the PD -1 cell surface membrane 
receptor, a negative regulatory molecule expressed by [CONTACT_93247] T and B lymphocytes. Inhibition of the interaction between PD-1 and its ligands promote immune responses and antigen -specific T cell 
responses to both foreign and self -antigens. PD -1 receptor blockade by [CONTACT_179474] a new approach for 
immunotherapy of tumors. Results from a Phase I/II study CA209003 indicate that nivolumab is active in 
multiple tumor types. Nivolumab 3 mg/kg monotherapy is currently being studied in phase 3 clinical trials 
in advanced melanoma, renal cell carcinoma (RCC) and non- small cell lung carcinoma (NSCLC) . 
 GBM, the most common primary brain tumor in adults, has an aggressive clinical course and a median survival of 12– [ADDRESS_211083] -line therapy with maximal surgical resection, radiation, and 
temozolomide. Bevacizumab is approved in the U nited States  for pat ients with progressive dis ease 
following therapy; no data has shown durable improvement of disease- related symptoms or OS. With 
limited efficacy of current therapy, more effective treatments to extend survival and preserve quality of life are needed. Ipi[INVESTIGATOR_125], a cytotoxic T -lymph ocyte antigen- 4 receptor blocking antibody, has shown 
clinical activity in advanced melanoma pat ients with brain metastases; preclinical studies demonstrate a 
benefit from combining a PD -[ADDRESS_211084] inhibitor with radiation in a mouse glioma model. Duke has a 
phase IIb, randomized, open- label study to evaluate the efficacy and safety of nivolumab alone or with 
ipi[INVESTIGATOR_125], v ersus bevacizumab in pat ients with recurrent GBM.  Patients  with KPS ≥70, grade IV 
malignant glioma treated with radiotherapy and temozolomide, and documented first GBM recurrence within 28 days of randomization are eligible. P atients with >1 recurrence of GBM, extracranial disease, 
autoimmune conditions, or previous VEGF inhibitor or anti -angiogenic treatment are ineligible. Safety 
cohort 1;  nivolumab 3 mg/kg [n=10; every 2 weeks  x 4] and nivolumab 1 mg/kg + ipi[INVESTIGATOR_125] 3 mg/kg 
[n=10; every 3 weeks  x 4 followed by [CONTACT_20382] 3 mg/kg every 2 weeks]  will establish safety and 
tolerability in GBM pat ients. Upon successful completion of cohort 1, efficacy cohort 2 will enroll up to 240 
pts with recurrent GBM, randomized 1:1:1 to receive nivolumab, nivolumab + ipi[INVESTIGATOR_125] (dosed as cohort 1), or bevacizumab (10 mg/kg every 2 weeks). The primary objectives are to evaluate safety in cohort 1 and OS in cohort 2, vs bevacizumab, with secondary objectives of PFS and ORR. Responses will be 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 14  
 assessed (Response Assessment Neuro- Oncology criteria) at the end of w eeks 6 and 12, and every 8 
weeks  until progression or treatment discontinuation. Clinical trial inform ation: [STUDY_ID_REMOVED]. 
7.2.2  DC Vaccine  
DC vaccine: Human Cytomegalovirus pp65- lysosomal -associated membrane protein mRNA -pulsed 
autologous dendritic cells  with granulocyte macrophage- colony stimulating factor . 
 
DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate CD4+ and CD8+ T -cells and B -cells [11, 12]. They are at the crossroads of many 
of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers [13-29]. 
 
Human CMV is an endemic β-Herpesvirus that does not usually cause significant clinical disease [30]. 
During primary maternal infection, however, human CMV can cause severe encephalitis in fetuses and 
lead to congenital brain defects. Human CMV disease is also a significant problem in 
immunocompromised adults such as organ transplant recipi[INVESTIGATOR_179446] [30]. Herpesviruses 
have also been implicated in a number of human malignancies including lymphoma, nasopharyngeal 
cancer, cervical cancer, and Kaposi’s sarcoma[ 31, 32] . Recently, expression of proteins unique to human 
CMV has been reported within a large proportion of malignant tumors including colorectal carcinoma, prostate cancer, and malignant astrocytomas [33-35]. Universal detection of the human CMV 
immunodominant protein pp65, immediate early gene 1 protein (IE1), and several other early antigens 
was demonstrated using IHC in Grade II -IV astrocytomas [35]. Presence of the virus in these samples was 
confirmed with ISH, PCR for human CMV -specific glycoprotein B (UL55), electron microscopic detection 
of intact virions [35], and direct detection of the virus from fresh operative samples in the shell vial assay  
(unpublished data). Human CMV antigens were not detected in surrounding normal brain samples, 
meningiomas, or brains affected by [CONTACT_114273], Alzheimer’s disease, paraneoplastic encephalitis, or Cryptococcal cerebritis.  
 The presence of highly -immunogenic human CMV antigens within MGs affords a unique opportunity to 
target these tumors immunologically. There is a vast amount of experience with both the safety and efficacy of immunotherapy targeting human CMV, and the presence of this virus  within brain tumors may 
allow this experience to be leveraged toward the effective eradication of MG expressing human CMV 
antigens. Adoptive T -cell therapy has been used to safely and successfully protect against CMV 
reactivation in myelodepleted BMT pati ents[36-39]. In addition, T -cell mediated immunotherapy has 
proven highly effective in the treatment of CMV -associated disease within the CNS and in the treatment 
of acute CMV infections [37, 40]. Tumors associated with other human Herpesviruses, such as Epstein-
Barr virus -associated lymphoma, including tumors within the CNS, have also been effectively treated and 
even large tumors have been cured by [CONTACT_179475] [41-46]. More recently, a vaccine directed against 
the potent  viral antigens of human papi[INVESTIGATOR_179447] -related cervical intraepi[INVESTIGATOR_179448] a prospective, randomized, double- blind trial.  
 
The potential for non- specific targeting of normal tissues is thought to be minimal in seropositive patients. 
After initial infection, CMV establishes lifelong latency in the infected individual, with cells of the myeloid lineage constituting a major reservoir for persistence of the virus. Virus can be detected within myeloid 
progenitors in the bone marrow, with a small portion of these cells demonstrating viral DNA replication 
without any detectable gene expression[ 47, 48]. Also a small p roportion (typi[INVESTIGATOR_897] 1 in 1,000 to 1 in 
10,000) of peripheral blood monocytes can be found to contain CMV DNA, while detection of viral RNA (gene expression) is not detected[ 49-51].   
 Vaccination specifically against CMV [ 52-56] has effectively reduced the risk of viral infection and 
transmission to fetuses in animal models [ 57-59] and in clinical trials [52, 56, 60-63]. Human clinical trials 
have also demonstrated some benefit of administering neutralizing antibodies in the treatment of human CMV infection[64 -67], highlighting the importance of the development of vaccination strategies that elicit 
both cellular and humoral immune responses. DCs strongly activate both T -cell and B -cell responses in 
Pro00065241:  AVERT  
Version: [ADDRESS_211085] been shown to be potent inducers of CMV -specific 
CTL responses in several studies [68-72], in addition to our own work which is outlined below.  
 
The use of RNA to encode tumor antigens for DCs was pi[INVESTIGATOR_179449]. Gilboa’s laboratory, but the ability of RNA- loaded DCs to stimulate potent antitumor immunity has been 
independently confirmed in murine and human systems [ 73-78]. In fact, there is accumulating evidence 
that RNA transfection represents a superior method for loading antigens onto DCs [ 75, 79]. This novel 
and innovative approach to DC antigen loading has multiple conceptual advantages over other forms of 
antigen delivery as well. RNA -based antigen loading does not require knowledge of major MHC 
restriction, and responses are not restricted to single MHC haplotypes or to a narrow B - or T-cell 
repertoire. This diversity increases the likelihood of inducing effective and sustained antitumor immune 
responses by [CONTACT_179476] T -cells [80-82]. Furthermore, in direct 
comparisons, RNA -loaded DCs have been found to be better stimulators of antigen- specific T -cells than 
other approaches [ 79]. Finally, RNA also carries a significant safety advantage, not possessed by [CONTACT_179477], in that it cannot be integrated permanently into the host genome. In addition to the preliminary data we present below, Kobayashi et al. , have demonstrated that tumor mRNA -loaded 
DCs can elicit a specific CD8+ CTL response against autologous tumor cells in patients with MG . 
 
7.2.3  Tetanus -Diphtheria Toxoid (Td)  
The current use of Td toxoid is for active immunization in children and adults against infection with the 
bacteria Clostridium tetani  and Corynebacterium diphtheria. Tetanus infection is manifested primarily by 
[CONTACT_34524] a potent exotoxin released by  C. tetani . Diphtheria is an acut e 
toxin -mediated infectious disease caused by [CONTACT_34525]  C. diphtheriae. Protection against 
disease is due to the development of neutralizing antibodies to the diphtheria toxin. Td toxoids adsorbed 
are readily available as several approved administrations [i.e. Daptacel (DTaP), Infanrix (DTap), Tenivac 
(Td adult), Boostrix (Tdap)] [83, 84]. Protection against disease is due to the development of neutralizing 
antibodies to the tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by 
[CONTACT_34526], is considered the minimum protective level.  A level ≥0.1 IU/mL by [CONTACT_179478] [ 85]. A serum diphtheria antitoxin level of 0.01  IU/mL, measured by 
[CONTACT_34526], is the lowest level giving some degree of protection; a level of 0.1 IU/mL by [CONTACT_179479].  Diphtheria antitoxin levels ≥1.0 IU/mL by [CONTACT_179480]-term protection.  
 
Following deep s.c./i.m. administration of the tetanus toxoid vaccine, toxoid molecules are taken up at the vaccination site by [CONTACT_34530], which are professional antigen- presenting cells. Within these cells, 
they are processed through the endosomal pathway (involving the phagolysosome) where they are bound to MHC type II molecules on the surface of DCs. The MHC II:toxoid complex then migrates to the cell 
surface. While this process is happening within the cell, the now activated mature DC at the vaccine site 
migrates along lymph channels to the draining lymph node where they encounter naive T
H2 cells, each 
with their own unique TCR. Identifying and then binding of the MHC II:toxoid to the specific T H2 receptor 
then activates the naive T cell, causing it to proliferate. Simultaneously, toxoid molecules not taken up b y 
DCs pass along lymph channels to the same draining lymph nodes where they come into contact [CONTACT_4490] B 
cells, each with their own unique B- cell receptor (BCR). Binding to the B cell through the specific 
immunoglobulin receptor that recognizes tetanus toxoid results in the internalization of toxoid, processing 
through the endosomal pathway and presentation on the cell surface as an MHC II:toxoid complex, similarly to DCs undergoing the same process.   These two processes occur in the same part of the lymph node with the result that the B cell with the 
MHC II:toxoid complex on its surface now comes into contact [CONTACT_179481] T
H2 whose receptors are 
specific for this complex. The process, termed linked recognition, results in the T H2 activating the B cell to 
become a plasma cell with the production initially of IgM, with a later switch to IgG antibodies produced. 
Additionally, a subset of these B cells becomes memory cells.  
 The novelty of using Td toxoid vaccination lies in the ability of this potent recall antigen to enhance 
antitumor responses as part of a cancer vaccination protocol. Td toxoid induces an inflammatory milieu 
Pro00065241:  AVERT  
Version: [ADDRESS_211086] with tumor -derived peptides, conditioning the vaccine 
site with Td toxoid has demonstrated enhanced immunogenicity with these peptides.  
 Our data from the ATTAC clinical trial (Duke IRB Protocol # Pro00003877) demonstrating the capacit y to 
enhance DC migration to VDLNs via Td pre- conditioning of the vaccine site offer potential therapeutic 
interventions whereby [CONTACT_179482] t umors [86]. In a completed randomized clinical trial, we 
found that migration of injected DCs to VDLNs following vaccine site pre- conditioning with Td toxoid was 
significantly increased compared to controls and that the efficiency of DC migration was strongly associ ated with clinical outcomes of patients with newly -diagnosed GBM, the most fatal type of malignant 
brain tumors. To address this observation, we took our Td pre- conditioning platform back into the 
preclinical setting using transgenic mouse models and were able to corroborate the effects of Td pre-conditioning on increasing the lymph node homing of intradermally administered DCs. Moreover, Td 
administration at a single vaccine site increases the migration of a bilateral DC vaccine to both inguinal 
lymph nodes. Regardless of the side of the Td intradermal skin prep, DC migration to bilateral inguinal VDLNs was equally increased, supporting a systemic response to recruit peripherally administered DCs.  
 Our Td pre- conditioning platform in the context of DC vaccination also elicited superior anti- tumor 
responses compared to controls receiving DC vaccines without Td pre- conditioning. In our clinical trial, 
patients with newly -diagnosed GBM who were administered the Td skin prep before DC vaccination 
revealed significantly longer progression- free and overall survival rates compared to the control cohort. In 
evaluating the relationship between DC migration and clinical responses, we observed a modest positive correlation between levels of DC migration and survival. In our preclinical model, Td pre- conditioning prior 
to vaccination with tumor antigen- specific DCs dramatically suppressed the growth of established and 
highly aggressive B16- F10/OVA tumors. The use of Td with a DC vaccine increased antitumor responses 
in an antigen- specific manner, as non- specific DC vaccines were not potentiated with Td pre- conditioning. 
Furthermore, in a challenge setting, where mice are administered the treatment platform prior to challenge with tumor inoculation, Td pre- conditioning at the vaccine site induced a significant survival 
benefit compared to controls . 
7.2.4  Pre-Clinical E xperience  
[IP_ADDRESS]  Nivolumab  
Preclinical animal models of tumors have shown that blockade by [CONTACT_4002] -1 by [CONTACT_66845] (mAbs) 
can enhance the anti -tumor immune response and result in tumor rejection. Antitumor activity by [CONTACT_4002] -[ADDRESS_211087] mechanisms (ie, expression of PD -L1 in antigen- presenting cell s) limit the 
antitumor response. Consequently, both PD -L1 positive and negative tumors may be targeted using this 
approach. In humans, constitutive PD -L1 expression is normally limited to macrophage- lineage cells, 
although expression of PD -L1 can be induced on other hematologic cells as well, including activated T 
cells. However, aberrant expression of PD -L1 by [CONTACT_66846] a number of human 
malignancies. PD -L1 expressed by [CONTACT_179483]-
specific T cells in vitro. Moreover, the expression of PD -L1 may protect the tumor cells from the induction 
of apoptosis by [CONTACT_20411] T cells .  
 
Preclinical data indicate that the combination of PD -1 and CTLA -4 receptor blockade may improve 
antitumor activity. In vitro combinations of nivolumab plus ipi[INVESTIGATOR_179450] -γ production 2- to 7-
fold over either agent alone in a mixed lymphocyte reaction. Increased antitumor activity of the 
combination was also observed in 3 of 5 syngeneic murine cancer models. In a murine melanoma vaccine model, blockade with either CTLA -4 or PD -1 antibodies  increased the proportion of CTLA -4 and 
PD-1-expressing CD4/CD8 tumor infiltrating T effector cells, and dual blockade increased tumor 
infiltration of T effector cells and decreased intratumoral T regulatory cells, as compared to either agent alone[87 ].  
 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 17  
 In a 4- week toxicity study of nivolumab in combination with ipi[INVESTIGATOR_179451]- dependent 
gastrointestinal (GI) toxicity. Histologic findings included inflammatory changes in the large intestine, 
which increased in incidence and severity in a dose- dependent manner. GI toxicity/colitis was not 
observed in cynomolgus monkeys administered nivolumab alone, but was observed in monkeys receiving ipi[INVESTIGATOR_125]. Nivolumab in combination with ipi[INVESTIGATOR_179452]/or medulla of the thymus and with acinar cell degranulation in the pancreas. Additional findings included interstitial mononuclear cell infiltrates in t he kidneys, portal mononuclear cell infiltrates in 
the liver and myeloid hypercellularity in the bone marrow. Nivolumab in combination with ipi[INVESTIGATOR_179453]- dose level (ie, 50 mg/kg and 10 mg/kg, respectively) was associated with the death of [ADDRESS_211088]. Please see nivolumab IB [88] for more information. 
[IP_ADDRESS]  DC Vaccines  
In our laboratories and those of others, systemic immunization using DCs co- cultured with 
uncharacterized tumor homogenate[ 89], whole tumor RNA [90], unidentified peptides eluted from tumor 
cells by [CONTACT_179484][ 91], or a distinct peptide encompassing the tumor -specific EGFRvIII 
mutation[92 ] have been shown to induce humoral and cell mediated systemic immune responses and to 
prolong the survival of rodents with brain tumors.  
 
In our laboratory, inbred VM/Dk mice received three or four weekly intraperitoneal injections of autologous bone marrow -derived DCs transiently co- cultur ed with tumor homogenate.  The homogenate was derived 
from a syngeneic murine astrocytoma cell line derived from a spontaneously occurring astrocytoma in the inbred VM/Dk  mouse strain. Splenocytes from mice immunized in this way were able, in vitro, to lyse the 
astrocytoma cell line that was used to generate the tumor homogenate. They were also able to lyse other astrocytoma cell lines derived from the same inbred mouse strain, but they had no effect against syngeneic fibroblasts. Similarly, these immunized mice also  demonstrated a significantly increased 
antibody titer against the astrocytoma cell line used to generate the homogenate. In addition, mice 
immunized with DCs transiently co- cultured with tumor homogenate that were subsequently challenged 
with a lethal dose of this astrocytoma cell line intracerebrally were found to have a median survival 
>160% longer than those immunized with DCs cultured without tumor homogenate (P=0.016). In addition, 
50% of the mice treated with the tumor homogenate- supplement ed DCs survived long- term without any 
evidence of tumor growth and also survived a rechallenge of tumor cells indicating that a sustained 
antitumor immune response had been established. These findings are especially significant in light of the 
fact that the astrocytoma cell line used is known to secrete the immunosuppressive agent TGF -β which is 
secreted by [CONTACT_179485] [93-97]. 
 
In another report from our laboratory [90], C57BL/[ADDRESS_211089] in vitro cytotoxicity assays again revealed that splenocytes harvested from mice immunized with DCs transiently co -cultured w ith either 
tumor -derived homogenate or whole tumor RNA were able to lyse B16F10 melanoma cells but not 
unrelated tumor cells from the same MHC background. In this experiment, mice immunized with autologous bone- marrow derived DCs co- cultured with tumor homogenate or whole tumor RNA increased 
median survival by >233% ( P=0.0006) and 48% ( P=0.0001), respectively, relative to mice immunized with 
DCs co -cultured with tumor homogenate or whole tumor RNA derived from an unrelated tumor with the 
same MHC background. In addition, 8/13 (61.5%) in the specific homogenate group and 4/10 (40%) in the specific RNA group survived beyond the endpoint of the study without evidence of tumor. Immunization of mice with pre- existing tumors with specific tumor homogenate also demonstrated the 
potency of this immunization approach by [CONTACT_179486] 62.5% relative to controls. In these mice an inflammatory infiltrate composed of mononuclear cells and polymorphonuclear leukocytes was identified only in mice treated with DCs c o-cultured with tumor homogenate that matched the intracerebral 
tumor challenge.  
 In a recent report from another laboratory, the survival of tumor- bearing rats injected subcutaneously with 
autologous bone marrow -derived DCs co- cultured with peptides eluted from tumor cells with a gentle acid 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 18  
 wash was significantly prolonged compared to tumor -bearing rats receiving equivalent numbers of DCs 
co-cultured with peptides acid- eluted from normal astrocytes ( P< 0.05).  Median survivals in these groups 
were 35 and 22 days respectively. In addition, three of the twelve rats (25%) treated with DCs co- cultured 
with acid -eluted tumor peptides remained alive at the end of the experiment. In addition, 
immunohistochemical analysis of five animals from each group in this experiment documented an 
increased peritumoral and intratumoral infiltration of CD8+T -cells, and to a lesser extent CD4+ T -cells and 
macrophages, in the group treated with DCs co- cultured with peptides acid- eluted from tumor cells when 
compared to controls . 
7.2.5  Clinical  Experience  
[IP_ADDRESS]  Nivolumab  
CA209003 is an ongoing Phase [ADDRESS_211090] previously treated advanced solid tumors, including melanoma, RCC, NSCLC, colorectal cancer, and hormone- refractory prostate cancer. Subjects received nivolumab at doses of 0.1, 0.3, 1, 3, or 10 mg/kg 
intravenously every 2 weeks, up to a maximum of 2 years of total therapy. As of 18- Mar-2013, a total of 
306 melanoma subjects were treated with nivolumab in the dose range of 0.1 - 10 mg/kg.  
 
No maximal tolerated dose was identified in CA209003. The incidence, severity and relationship of AEs 
were generally similar across dose levels and tumor types. Nivolumab related AEs of any grade occurred in 75.2% of subjects. Of the 306 treated subjects, 303 (99.0%) subjects have at  least  [ADDRESS_211091]  frequently reported   AEs were fatigue (54.9%), decreased appetite 
(35.0%), diarrhea (34.3%), nausea (30.1%), and cough (29.4%). Treatment -related AEs were reported in 
230 (75.2%) of the [ADDRESS_211092] frequently reported treatment -related AEs were fatigue 
(28.1%), rash (14.7%), diarrhea (13.4%), and pruritus (10.5%). Most treatment -related AEs were low 
grade. Treatment -related high grade (Grade 3- 4) AEs  were reported in 52 (17.0%) of subjects. The most 
common treatment -related high grade AEs were fatigue (2.3%) and diarrhea (1%).  
 Drug- related SAEs occurred in 11.5% of subjects. Grade 3- [ADDRESS_211093] 2 
subjects included: diarrhea (3 subjects, 1.0%), pneumonitis (3 subjects, 1.0%),  pneumonia (2 subjects, 
0.7%) and lipase increased (2 subjects, 0.7%).  
 Select AE categories (events with a potential inflammatory mechanism requiring more frequent monitoring and/or unique intervention such as immunosuppressants and/or endocrine replacement therapy) include: 
GI AEs, pulmonary AEs, renal AEs, hepatic AEs, skin AEs, and endocrinopathies. In addition, select AEs 
include a category for infusion reactions. Each category is composed of a discrete set of preferred terms, 
including those of greatest clinical relevance. These select AEs are considered events of interest based on the mechanism of action and were previously referred to as immune- related AEs or immune- mediated 
AEs.  
 The 10 mg/kg cohort had numerically greater frequency of high- grade select AEs including the 
subcategories of endocrinopathies, GI, pulmonary, and infusion reactions. Most high grade events resolved following the treatment guidelines for the treatment of pulmonary events, GI events, hepatic events, renal events, and endocrine events, respectively . 
 In CA209003 (MDX1106- 03), the clinical activity of nivolumab was demonstrated in a variety of tumor 
types and across a range of doses (0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,  10 mg/kg). As of the clinical 
cut-off date of 05- Mar-2013, a total of [ADDRESS_211094] 1.0, has been reported at all dose levels.  
 
Among 107 patients with advanced melanoma who received nivolumab, the preliminary objective 
response rate was 33/107 (31%). Responses occurred at each dose level, with 6/17 (35%), 5/18 (28%), 11/35 (31%), 7/17 (41%), and 4/20 (20%) melanoma subjects responding at  0.1, 0.3, 1, 3, and 10  mg/kg, 
respectively.  Duration of response ranged from 24.1 to 48.7
+, 18.4 to 66.3+, 32.4 to 108.1+, 40.1+ to 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 19  
 115.4+, and 73.9 to 117.0+ months in melanoma subjects treated at 0.1, 0.3, 1, 3, and 10 mg/kg, 
respectively. An additional 7% of melanoma subjects had stable disease for 24 weeks or longer. Across 
dose levels, melanoma subjects achieved a median overall survival of 16.8 months (95% CI: 12.5, 31.6), 
with a 2- year overall survival rate of 43%.  
 Here at Duke, w e are currently enrolling in CA209 143, “A  Randomized Phase 3 Open Label Study of 
Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination With Ipi[INVESTIGATOR_179454]” where w e evaluate the ef ficacy and safety of 
nivolumab alone or with ipi[INVESTIGATOR_125], vs bevacizumab in subject s with recurrent GBM. Subjects  with K PS 
≥70, grade IV malignant glioma treated with radiotherapy and temozolomide, and documented first GBM 
recurrence within 28 days of randomization are eligible. Those with >1 recurrence of GBM, extracranial 
disease, autoimmune conditions, or previous VEGF inhibitor or anti -angiogenic treatment are ineligible. 
Safety cohort 1; nivolumab 3 mg/kg [n=10; Q2W x 4] and nivolumab 1 mg/kg + ipi[INVESTIGATOR_125] 3 mg/kg [n=10; Q3W x 4 followed by [CONTACT_20382] 3 mg/kg Q2W]) will establish safety and tolerability in GBM pts. Upon 
successful completion of cohort 1, efficacy cohort 2 will enroll up to 240 pts with recurrent GBM, 
randomized 1:1:1 to receive nivolumab, nivolumab + ipi[INVESTIGATOR_125] (dosed as cohort 1), or bevacizumab (10 mg/kg Q2W). The primary objectives are to evaluate safety in cohort 1 and OS in cohort 2, vs 
bevacizumab, with secondary objectives of PFS and ORR. Responses will be assessed (R ANO  criteria) 
at the end of w eeks 6 and 12, and every 8 weeks  until progression or treatment discontinuation. Clinical 
trial information: [STUDY_ID_REMOVED].   To date, nivolumab has been well tolerated in this patient population – 
[ADDRESS_211095] been treated on the nivolumab monotherapy arm.  
 Please see nivolumab IB [88] for more information. 
[IP_ADDRESS]  DC Vaccines 
The occurrence of human DCs in the peripheral blood is low (0.15% of circulating mononuclear cells), and procedures to isolate circulating DCs are cumbersome, relying on negative selection techniques to deplete the mononuclear cell fraction of contaminating monocytes and lymphocytes. Furthermore, brain 
tumor patients are characteristically immunosuppressed either from the use of steroids or due to the fact 
that malignant brain tumors secrete immunosuppressive agents like TGF -y. We have been using a simple 
method described previously [117] , to generate human DCs by [CONTACT_179487] -CSF and IL- 4. We have compared the ability to generate DCs from patients with malignant brain 
tumors and patients undergoing craniotomy for non- tumor re lated procedures. The phenotype of DCs 
from both tumor and normal populations were identical and were characterized as being highly positive for HLA -ABC and HLA -DR, the co- stimulatory molecules CD80 and CD86, and the DC/monocyte marker 
CD11c, but negative for the monocyte marker CD14. The cells were negative for the B and NK cell 
lineage markers, CD19 and CD56, respectively, which is consistent with published DC phenotypes.  
 DC immunotherapy in patients with MGs has been evaluated in only a few studies. In the published study 
by [CONTACT_36868]. [118] , patients received biweekly intradermal injections of peripheral blood derived DCs 
pulsed with uncharacterized peptides eluted from the surface of autologous glioma cells by [CONTACT_179488]. All patients were required to complete a course of RT and were off steroids at the time of immunization. Toxicity was minimal and included only mild fever and lymphadenopathy. There was no clinical or radiographic evidence of autoimmune encephalomyelitis in any patient and no serious adverse events occurred. The immunization resulted in enhanced CTL activity in 4/[ADDRESS_211096] infiltrated the patient’s tumors whom underwent reoperation after 
immunization. Although this study  was performed in a selected population of patients, the median survival 
of 455 days in the treated group compared very favorably with an institutional control group where median 
survival was only 257 days. Similarly, when immunized patients were compared to expected outcome per Curran’s recursive partition analysis, which controls for known prognostic factors (Karnofsky Performance Status, histology, surgery, mental status, etc .), the results still appeared quite favorable. Unfortunately, no 
clinical respo nses were seen and any antigen- specific immune response could not be characterized 
because the immunizing antigens were not characterized.  
 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 20  
 A study by [CONTACT_179489]. (2001) [119] used autologous DCs fused with autologous tumor cells as an 
immunogen in an 8 patient trial. The immunization schedule consisted of 3 to 7 vaccinations 3 weeks 
apart given intradermally. All vaccinations were well tolerated.  
 In another Phase I/II trial, tumor lysate pulsed DCs were given to ten patients who received immunizations every three weeks for a minimum of one and a maximum of [ADDRESS_211097] tumor lysate- pulsed DCs were increased in two patients [120] . In a 
more recently published study, patients with GBM were treated with 1 x 10
6 to 1 x 107 DCs pulsed with 
acid eluted autologous tumor peptides [121] . There was no evidence of DLT or serious adverse events. 
One patient had an objective clinical response documented by [CONTACT_9252], and six patients developed measurable systemic antitumor CTL responses . 
 In a more recent study, Kikuchi et al. [98] investigated the safety and clinical response to immunotherapy 
using fusions of DCs and glioma cells combined with recombinant human IL- 12 for the treatment of MG. 
Fifteen patients with MG participated in this study. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells were prepared from DCs and glioma cells using polyethylene glycol. All patients received fusion cells intradermally on day 1. IL- 12 was injected 
subcutaneously at the same site on days 3 and 7. No serious adverse effects were observed. In four patients, magnetic resonance imaging showed a greater than 50% reduction in tumor size.  One patient 
had a mixed response. In our ongoing Phase I/II clinical trial (BB IND 9944) patients with newly -
diagnosed MGs are vaccinated with mature DCs loaded with a peptide spanning the fusion junction of 
EGFRvIII conjugated to keyhole limpet hemocyanin (PEPvIII -KLH) (500 mcg/immunization), mixed with 
GM-CSF (approx. 150 mcg/immunization). EGFRvIII is a tumor specific antigen, which is expressed on 
approximately 47% of all MGs. The vaccination protocol consists of [ADDRESS_211098] been enrolled with 16 completing vaccination with no adverse events. No patient showed a 
positive delayed- type hypersensitivity reaction to KLH or PEPvIII before vaccination and of the evaluable 
patients after vaccination, 14/15 (93.3%) patients reacted to KLH and 11/15 (73.3%) reacted to PEPvIII. 
In vitro proliferation in response to PEPvIII was seen in 11/12 (92%) and to KLH in 9/12 (75%) of patients 
tested. Two patients, one with anaplastic astrocytoma and one with GBM with residual radiographic disease after resection, and radiation, have had a nearly complete response in our prior vaccination study 
which also included the use of chemotherapy agents such as TMZ. These patients have remained stable for 174.9 and 217.3 weeks. Of the 14 patients without radiographically evident disease, 4/14 (28.6%)  
have not progressed at 102.7, 171.3, 180.7, 430.7 weeks with a median overall time to progression of 10.4 months comparing favorably with a historical unvaccinated cohort (EGFRvIII positive and gross total resection) that had a median TTP of 7.1 months (n=39).   For patients with GBM, the median survival time 
was 20.0 months which compares favorably with recently published trials evaluating newly -diagnosed 
patients with GBM treated with GLIADEL®(13.9 months) [99]; r adiation and concurrent TMZ (14.6 
months);  or radiolabeled anti -tenascin monoclonal antibodies performed at Duke University  (18.3 
months) [100]. 
 
7.3 Study Purpose/Rationale 
 Immune checkpoint blockade is a rapi[INVESTIGATOR_179455]- oncology 
and treatment with investigational agents targeting this mechanism has induced regressions in several types of cancer. Cytotoxic T -lymphocyte –associated antigen 4 (CTLA- 4) and programmed death 1 (PD -1) 
receptor are two important cellular targets that play complementary roles in regulating adaptive immunity. Wher eas PD -[ADDRESS_211099] alone[ 87]. 
 CMV antigens have been identified in GBM and may make excellent antitumor immunotherapeutic targets. Vaccination and adoptive T  cell strategies targeting CMV in humans in other contexts have been 
safe and effective. DC vaccinations targeting other antigens in GBM have been safe and effective. Other 
Pro00065241:  AVERT  
Version: [ADDRESS_211100] shown that immunosuppressive T Regs are disproportionately represented in the blood and 
tumors of patients with malignant gliomas (MGs). This finding is accompanied by [CONTACT_179490] T  cell 
dysfunction resulting in a profound immunosuppression[ 101, 102] that like ly significantly limits 
endogenous antitumor immune responses.  Programmed cell death 1 (PD -1) is a key immune receptor 
expressed by [CONTACT_93247] T cells that mediates immunosuppression.  Blockade of PD -1 may help overcome 
immune resistance. Nivolumab is a fully human monoclonal immunoglobulin (Ig) G4 antibody that binds to the PD -1 cell surface membrane receptor, a negative regulatory molecule expressed by [CONTACT_93247] T and B 
lymphocytes. Inhibition of the interaction between PD -1 and its ligands promote immune responses and 
antigen- specific T cell responses to both foreign and self -antigens. PD -1 receptor blockade by [CONTACT_179491] a new approach for immunotherapy of tumors . 
 
We believe the use of serial vaccination in conjunction with an anti -PD-1 monoclonal ant ibody, is a novel 
platform for enhancing the efficacy of tumor -specific vaccines.  In addition, immune checkpoint receptors 
such as program death- ligand (PD -L)1/B7- H1/CD274, a transmembrane receptor ligand and negative 
regulator of T  cell signaling, have been reported to be upregulated in gliomas. Studies have also 
suggested an association   between   malignancy   grade   of   astrocytic   tumors   and   tumor   cell   PD -
L1 expression.  Additionally , use of an inhibitor of PD -L1 in mouse glioma models suggests benefit in 
combination with radiation therapy.  
 
We have demonstrated in murine models that DCs loaded with tumor -specific antigens in the form of 
mRNA can induce potent and specific humoral and cell -mediated immune responses that are effective 
agains t murine i.c. tumors, including a syngeneic murine astrocytoma, without inducing autoimmunity [89, 
92, 103]. Our previous clinical experience has also shown that DC vaccines in combination with standard of care radiation therapy and chemotherapy are capable of generating potent, tumor -specific immune 
responses and clinical radiographic responses in patients with MGs. We and others have also shown that antigens derived from CMV are contained within MGs and may serve as potent and specific immunotherapy targets. Vaccination and adoptive T -cell strategies targeting CMV in humans in other 
contexts, including the targeting of lesions within the CNS, have been safe and effective. We have also 
shown that DCs generated from patients with GBM and loaded with pp65- LAMP mRNA are capable of 
generating CD4+ and CD8+ T -cells that produce IFN -γ and kill malignant astrocytes infected with CMV in 
an antigen- specific fashion. We have found that TILs isolated from these patients are significantly 
enriched for T -cells that specifically recognize CMV antigens, suggesting that this response may be 
important in the biology of these tumors.  
 Surgery alone has not been established as the standard of care treatment  in the recurrent brain tumor 
population, rather, it is used in combination with medical treatment. Therefore, it is our belief that providing nivolumab treatment ± DC vaccine prior to surgery will be safe and well tolerated.  However, subjects will be closely monitored for any indication that surgical resection should be performed sooner than the planned schedule.  Therefore, we would like to evaluate the safety of nivolumab in combination 
with DC vaccinations for the treatment of bevacizumab- naïve subjects  with first or second recurrent, 
resectable WHO Grade III and IV MGs  and to assess  the immunologic  changes  from nivolumab therapy  
with and without DC .  In order to do that, we will randomize subjects to two groups: Group I will receive 
nivolumab monotherap y until surgical resection, and Group II will receive nivolumab with DC vaccine 
therapy until surgical resection.  During surgical resection blood and tumor samples will be assessed and compared.  Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until  confirmed progression.  The purpose of the surgical resection is de -bulking of the tumor .  The 
subject will continue on study treatment  following surgery, at the discretion of the treating physician, until 
they have radiographic or clinical progression (as described in Section  12.2.1) , regardless of the 
pathology results from surgery . 
  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 22  
  
8 OBJECTIVES AND ENDPOINTS  
 
Table 1: Objectives and Endpoints  
  Objective  Endpoint  Analysis  
Primary  To evaluate the safety of 
nivolumab in combination 
with DC vaccinations for the treatment of 
bevacizumab- naïve 
subjects with first or 
second recurrent, resectable WHO Grade III 
and IV MGs.  Proportion of patients with 
unacceptable toxicity.  See Section 15.[ADDRESS_211101] of 
pre-surgical treatment on 
gene expression  Mean or median change in 
the level of gene expression 
in PBMCs, and mean or 
median level of gene 
expression in tumor  See Section 15.6.4  
Exploratory  To determine if evidence 
exists for epi[INVESTIGATOR_179456].  Changes in TCR repertoire 
diversity  TILs, and PBLs.  See Section 15.6.5  
  
9 INVESTIGATIONAL PLAN  
9.1 Study D esign  
 This two -arm randomized trial  (please see section 9.1.9 for details)  will evaluate the safety of nivolumab 
in combination with DC vaccinations for the treatment of bevacizumab- naïve subjects with first or second 
recurrent, resectable WHO Grade III  and IV MGs. Up to 66 patients will be enrolled and treated with the 
goal of accruing 30 patients (15 per arm) that will receive nivolumab and a t least  3 vaccines. After 
enrollment, leukapheresis will be done for generation of DC vaccines and immunologic m onitoring (please 
see s ection 12 .7.5
 for details) . Following consent , all subjects will undergo standard of care tetanus 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 23  
 booster vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscul arly (I.M.)  
into the deltoid muscle to ensure adequate immunity to the tetanus antigen. All subjects  will initially return 
every 2 weeks and receive approximately 3 infusions of  nivolumab 3 mg/kg IV while the DC vaccines are 
being prepared from the initial leukapheresis , Nivolumab infusions will continue until the DCs are ready 
for vaccinations. All subjects will then be randomized 1:1 to one of 2 arms (Group I: nivolumab only pr e-
surgery; Group II: nivolumab with DC vaccines pre- surgery) . Patients who are unable to tolerate 
nivolumab will be withdrawn from the study and replaced. Patients  whose DCs or PBLs fail to meet 
release criteria will continue to receive nivolumab only  and will not undergo repeat leukapheresis . For 
patients whose leukapheresis yields less than 4 vaccines, repeat leukapheresis may be obtained a 
minimum of 2 weeks from the previous leukapheresis  (and may be repeated as needed)  if pre -pheresis 
blood work is within the Apheresis Center’s parameters  and as long as this will not cause a significant 
delay in treatment for the patient .  For patients that need to come off study due to adverse events, they 
will be eligible for surgery and other treatment modalities. Patients will be monitored closely and those patients that have clinical indications for surgical resection prior to the timeframe indicated below will be 
withdrawn from the study and undergo surgical resection. Peripheral blood will be drawn for immune 
moni toring prior to treatment with the 5
th cycle  of nivolumab ( second post -randomization infusion of 
nivolumab) .  
 All vaccines will be administered intradermally near each groin, divided into 2- [ADDRESS_211102] be performed using an 
appropriate needle for intradermal administration.  A 25- gauge needle is recommended.   
 
Group I Treatment Plan (Nivolumab Only Pre- Surgery)  
After randomization, patients in Group I will receive nivolumab 3 mg/kg IV every [ADDRESS_211103] will then undergo surgical resection of tumor within approximately  1-3 weeks by a 
Duke neurosurgeon. Approximately 2– [ADDRESS_211104] 
will resume nivolumab 3mg/kg IV every two weeks with DC vaccine administration intradermally for a total of [ADDRESS_211105]  DC vaccine, patients will receive vaccine site pre- conditioning.  A 
single dose of Td toxoid ( 1 flocculation unit, Lf, in 0. 4 mLs of saline) will be administered to a single  side 
of the groin i.d. (as described above for all vaccine administrations) 12-[ADDRESS_211106]  DC 
vaccine, which is always given bilaterally at the groin site.  At the vaccine # 3 visit, prior to vaccine # 3 
administration, erythema and induration measurements will be taken of pre- conditioning site. Group I 
subjects will then receive monthly DC vaccine administrations intradermally for 5 months or until 
progression (whichever comes first).  Total vaccines to be administered will be [ADDRESS_211107] vaccine 
(#8), subjects will have per ipheral blood drawn for immune monitoring prior to infusion of nivolumab.  
 
Group II Treatment Plan (Nivolumab with DC Vaccines Pre- Surgery)  
After randomization, patients in Group II will receive the fourth cycle of nivolumab then receive nivolumab 
3 mg/kg IV along with DC vaccines intradermally every [ADDRESS_211108]  DC vaccine, patients will receive vaccine site pre- conditioning.  A single 
dose of Td toxoid ( 1 flocculation unit, Lf, in 0. 4 mLs of saline ) will be administered to a single side of the 
groin i.d. (as described above for all vaccine administrations) 12-[ADDRESS_211109]  DC vaccine, 
which is always given bilaterally at the groin site.  At the vacci ne #3 visit, prior to vaccine # [ADDRESS_211110] will resume nivolumab 
3mg/kg IV every two weeks . When DC vaccines have completed processing and are available for 
administration,  DC vaccine administrations as described above will resume monthly  for 5 months or until 
progression (whichever comes first). Total vaccines to be administered will be 8 ( [ADDRESS_211111]-
surgery) unless subject is removed.  Nivolumab will continue until progression.  At the clinic visit following 
the last vaccine (#8), subjects will have peripheral blood drawn for immune monitoring prior to infusion of 
nivolumab.  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 24  
  
9.1.1  D efinition of Unacceptable Toxicity 
Toxicities will be graded according to the NCI CTCAE version 4 criteria. An unacceptable toxicity is 
defined as any grade 3, 4, or 5 adverse event that is possibly, probably, or definitely related to either nivolumab or DC vaccination treatment during concurrent treatment, or any Grade 2 drug- related uveitis 
or eye pain or blurred vision that does not respond to topi[INVESTIGATOR_20308] 1 severity within the re -treatment period OR requires systemic treatment .  In addition, a ny complicat ion 
following resection (ex. excessive intracranial bleeding , delays in wound healing) that are prolonged 
longer than 4- [ADDRESS_211112] -surgery will be considered an unacceptable toxicity.   
9.1.2  Dose Modification  
The DC vaccine and nivolumab dose will not be modi fied in this trial.   Please see the nivolumab IB  and 
Section 12.2.2 for discontinuation of nivolumab related to adverse events.  
9.1.3  Safety Considerations  
Management of  Toxicities  
If a Grade 3 NCI CTC or greater toxicity is seen that is not attributable to a concomitant medication (other than nivolumab or vaccine), co- morbid event, or disease progression that has been documented 
radiographically or clinically, the next scheduled study -specific treatment  for that patient  (nivolumab 
and/or DC vaccine)  will be withheld for up to 2 months or until the NCI CTC toxicity improves to a Grade 2 
or until the KPS score returns to within 10 points of baseline.  
 
Long Term Survivors  
For subjects still actively receiving study treatment ≥ [ADDRESS_211113] 
nivolumab held or delayed . 
 
Adverse Event Reporting and Documentation  
An “Adverse Event” will be defined as any adverse change from the subject’s pre- treatment baseline 
condition, including any clinical or laboratory test abnormality that occurs during the course of research after initiation of nivolumab.  Adverse events will be categorized and graded in accordance with the NCI 
CTC (Version 4).   AEs and SAEs will be collected starting at the time of consent.  
 A “Serious Adverse Event” will be defined as an undesirable sign, symptom or medical condition which 1) is fatal or life threatening; 2) requires inpatient hospi[INVESTIGATOR_26109] a prolongation of existing hospi[INVESTIGATOR_059]; 3) results in persistent or significant disability/incapacity; 4) constitutes a congenital anomaly or a birth defect and/or; 5) medically significant such that it may jeopardize the subject, and may require medical or 
surgical intervention to prevent one of the outcomes listed above.  
Please see section [ADDRESS_211114]’s antihistamines to be held before and following vaccine administrations.  
 
Pro00065241:  AVERT  
Version: [ADDRESS_211115] -resection.  
Bevacizumab will be administered at 5mg/kg IV QOW following nivolumab infusion and can be increased 
to 10mg/kg IV QOW if needed.  Bevacizumab will not be provided by [CONTACT_1758] . 
 
9.1.7  Missed Doses  
To ensure that repetitive infusions of nivolumab and DC  vaccines  will be given to patients, both will be 
given within  approximately  ± [ADDRESS_211116] may be removed from the trial at the discretion of the study PI .  Please see the nivolumab IB [88] on management of missed doses of nivolumab.  
9.1.[ADDRESS_211117] and recorded at each study visit by [CONTACT_5051] . 
9.1.9  Randomization 
Permuted block randomization will be used to assign patients to one of two treatment arms  (Group I: 
nivolumab monotherap y until surgery  and Group II : nivolumab with DC vaccine therapy  until surgery ).  
The randomization module for the Duke electronic database system (Title 21 CFR Part 11 C ompliant ) will 
be used for this purpose.  
9.2 Rationale for Selection of Dose, Regimen, and Treatment Duration  
 
Nivolumab 
Nivolumab will be infused at a dosage of 3 mg/kg IV every other week (+/ - approximately 2 days) over 
approximately 30 -60 minutes.  Each infusion of nivolumab will be considered one cycle.  On the days 
where patients receive both nivolumab and DC vaccine, the order of the administration does not matter (i.e., DC vaccine can be administered before or after nivolumab and does not need to be given in the same order at follow -up visits) . 
 
Single -dose pharmacokinetics (PK)  of nivolumab was studied in 39 subjects with cancer. The single- dose 
PK of nivolumab was linear and dose- proportional in the range of 0.3 mg/kg to 10 mg/kg. The mean 
terminal T -HALF of nivolumab ranged between 17 and 25 days across the dose range of  0.3 mg/kg to 10 
mg/kg.  Geometric mean total clearance varied from 0.13 mL/h/kg to 0.19 mL/h/kg, while mean volume of 
distribution varied between 83 mL/kg and 113 mL/kg across doses. The clearance and half -life of 
nivolumab are consistent with that of IgG4.  
 
The multip le-dose PK of nivolumab given every 2 weeks  was determined from MDX1106- 03 study as well 
as by [CONTACT_179492]  669  subjects  across  nivolumab  studies.  Multiple -dose PK of 
nivolumab following every 2 week  dosing was linear with dose- proportional increase in Cmax and AUC  
(TAU) in the studied range of 0.1 mg/kg to 10 mg/kg.  Nivolumab accumulation with every 2 week  dosing 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 26  
 frequency was in the range of 2.9 to 3.3 based on AUC  (TAU),  2.[ADDRESS_211118]  been  assessed  in  approximately 32 clinical studies  sponsored  by  [CONTACT_179493].,  Ltd.  (ONO):  [ADDRESS_211119] received nivolumab monotherapy in single- or multiple -dose Phase 1/2/3 studies or studies with nivolumab in combination with other 
therapeutics (ipi[INVESTIGATOR_125], cytotoxic chemotherapy, anti -angiogenics, and targeted therapi[INVESTIGATOR_014]). The 
descript ion and status of all studies are outlined briefly in the nivolumab IB [88]. Results from the ongoing 
studies are p reliminary and are subject to change. 
 
DC Vaccine  
Only 1 dose level of DCs (2 x 107) will be given.   
 
Vaccination and adoptive T -cell strategies in humans in other contexts have been safe and effective. 
Therapeutic TMZ induces a profound lymphopenia that may enhance anti -tumor vaccination responses 
when given during the homeostatic T -cell proliferation that occurs in response to lymphodepletion. Other 
DC vaccines given to patients with high- grade gliomas during recovery from TMZ -induced lymphopenia 
have produced potent tumor -specific immune responses and have been well tolerated.  
 In one of our dendritic cell immunotherapy trials (Pro00003877 ATTAC), we evaluated the impact of 
vaccine site pre- conditioning with Td toxoid. Patients randomized to Td showed increased dendritic cell 
migration bilaterally and significantly improved progression- free and overall survival. Furthermore, we 
observed a modest association between effective DC migration to VDLNs and clinical outcomes [86]. 
9.[ADDRESS_211120] will be considered “on study”  and the patient will be monitored 
for al l AEs and SAEs . Rationale for taking patient off protocol treatment will be documented. 
9.5 Early Study Termination 
 
This study can be terminated at any time for any reason by [CONTACT_978] -sponsor. If this occurs, all subjects on 
study should be notified as soon as possible. Additional procedures and/or follow up should occur in 
accordance with Section 12.7. Section 12.6 describes procedures and process for prematurely withdrawn 
patients . 
 
10 STUDY DRUG 
10.1 Names, Classification, and Mechanism of Action 
 
Nivolumab 
Nivolumab (also referred to as BMS -936558 or MDX1106) is a fully human monoclonal antibody (HuMAb; 
immunoglobulin G4 [IgG4] -S228P) that targets the programmed death- 1 (PD -1) cluster of differentiation 
279 (CD279) cell surface membrane receptor . PD-1 is a negative regulatory molecule expressed by 
[CONTACT_179494]00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 27  
 activated T and B lymphocytes.   Binding of PD -1 to its  ligands, programmed death– ligands 1 (PD -L1) and 
2 (PD -L2), results in the down- regulation of lymphocyte activation. Inhibition of the interaction between 
PD-1 and its ligands promotes immune responses and antigen- specific T  cell re sponses to both foreign 
antigens as well as self -antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is 
produced using standard mammalian cell cultivation and chromatographic purification technologies. The 
clinical study product is a sterile solution for parenteral administration.  Please see nivolumab IB [88] for 
more inf ormation. 
 
DC Vaccine  
Human CMV  pp65- LAMP mRNA -pulsed autologous DCs is the name [CONTACT_179514]. The class of action for the DC vaccine is a biological. 
 
Tetanus -diphtheria toxoid (Td toxoid adsorbed)  
Td is indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single 
dose; substitute 1- time dose of Tdap for Td booster, then standardly boost with Td every 5- 10 years. 
Please refer to section 7.2 on the use of Td in this protocol. The class of action for the tetanus toxoid is an 
antitoxin.  
 
Leukapheresis and dendritic cell vaccine generation  
Two leukapheresis procedures will be p erformed i n this protocol. The leukapheresis will be used for DC 
generation and immune monitoring. Leukaphereses will be approximately a 4- hour leukapheresis. It is 
estimated that 10- 12 L of blood will be processed during this leukapheresis.  
 DCs will be generated from leukapheresis in vitro  by 7-day culture with GM- CSF and IL- 4. PBMC for in 
vitro generation of DCs will be obtained by [CONTACT_179495]. For patients without sufficient 
venous access for leukapheresis a temporary intravenous catheter may be inserted.  
 At the end of the 7 day incubation for generation of DC a sample of the media is taken for mycoplasma testing, the cells are then harvested and electroporated with pp65- LAMP mRNA. The DCs are placed in a 
flask with AIM V media GM -CSF + IL -4 + TNF -α + IL -6 + IL -1β at 37
OC, 5% CO 2 for 18- 20 hours for 
maturation. The cells are washed twice with PBS and frozen at 2-4 x 107 cells/mL in 90%  autologous 
human AB serum (Valley Biomedical, Winchester, VA [ZIP_CODE]), 10% DMSO and 5% glucose in a controlled- rate freezer at a rate of 1
oC/minute.  
 The DCs are then stored until needed at – 135
oC.  After freezing, an aliquot of cells is thawed for QA/QC.  
This testing will look at viability, (>70%) endotoxin content, (<5 E.U. /Kg B.W.) mycoplasma contamination 
(negative) and sterility testing for aerobic and anaerobic bacterial cultures (1 x 106 DCs) and fungal 
cultures (1 x 106 DCs).  
 
For each vaccination, cells that have passed QA/QC will be rapi[INVESTIGATOR_179457] 37oC, washed three times 
with PBS and counted. The cell concentration will be adjusted to 5 x 107 cells/mL and DCs will be 
resuspended in preservative free saline and placed into a sterile tuberculin syringe with a 27 gauge 
needle.  
 From the final preparation a sample of cells will be sent for Gram stain and endotoxin testing prior to administration. DC vaccination will not be given until endotoxin testing has been passed (< 5.0 E.U/Kg) and the Gram stain has been found to be negative. An aliquot of cells will also be sent for aerobic and 
anaerobic bacterial cultures (1 x 10
6 DCs) and fungal cultures (1 x 106 DCs).  
 
In the event of a positive sterility or mycoplasma test, the Principal Investigator [INVESTIGATOR_179458]. The FDA and IRB will be notified within 15 calendar days. The patient will be asked to be evaluated by a physician within 24 hours. If the patient has or develops a temperature >38.5
oC or clinical evidence of infection at the injection site (drainage, erythema or edema) 
or systemically, the patient will have swabs taken from the injection sites (if possible), along with blood, urine and sputum (if possible) sent for bacterial, fungal, and mycoplasmal culture and sensitivity testing.  
Pro00065241:  AVERT  
Version: [ADDRESS_211121], and an independent infectious disease consultation will be 
obtai ned to guide further therapy. Any remaining immunization samples will be sent for sent for bacterial, 
fungal, and mycoplasmal culture and sensitivity testing and endotoxin testing, and immunizations will 
proceed only if the patient fully recovers and subsequent samples are found to be sterile. 
10.2 Packaging and Labeling 
 
• For nivolumab:  (Please see Appendices for BMS Guidelines  for packaging and labeling)  
Name  
[CONTACT_179515]: nivolumab 
Lot #: Lot XXX  
Caution New Drug Limited By [CONTACT_34541]  
 
• For CMV pp65- LAMP mRNA- pulsed DCs  (DC vaccine) : 
Name  
[CONTACT_179515]:  pp65DCs  
Lot #: Lot 001  
Caution New Drug Limited By [CONTACT_179496] e 
 
• For tetanus diphtheria toxoid  
Name  
[CONTACT_179515]: Td  
Lot #: Lot 001  
10.3 Supply, Receipt, and Storage 
 
The DCs will be stored in a locked liquid nitrogen freezer in the FDA -approved Clinical Processing Suite 
in the DBTIP Laboratory. The Nautilus LIMS (Laboratory Information Management System) database will 
track receipt and storage location . 
 These study agent s are supplied and stored by [CONTACT_179497]  (ICS) : 
nivolumab is supplied in a single use glass vial , Bristol-M yers Squibb, NJ ; and Tetanus D iphtheria T oxoid 
adsorbed, s tored at 4
oC.  
 
10.4 Dispensing and Preparation 
 The DC products will be delivered from the DBTIP Laboratory directly to the bedside under the supervision of the research nurse, or his/her designee. DCs will be administered according to protocol. 
The patient’s name, Study ID, DOB, and Duke history number  will be double verified prior to DC 
administration as is standard Duke BMT transfusion procedure. The nivolu mab will be dispensed from the 
Duke Investigational Chemotherapy Service to the Duke Cancer Center’s Oncology Treatment Room where infusion will take place per standard operating procedures for that clinic . The tetanus will be 
dispensed from the Duke Investigational Chemotherapy Services (ICS)  Pharmacy . 
10.5 Compliance and Accountability 
 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 29  
 The DC vaccines will be stored in the BTIP in a temperature controlled, locked access controlled storage 
unit. A drug log sheet will be used to track and document the drug. The products will be signed out and 
distributed by [CONTACT_179498]. The Duke BTIP personnel use safe medication practices to 
reduce the risk of medication errors and adverse events when setting up study drug procedures. Investigational drugs are ordered, received, stored, and dispensed for BTIP protocols that are approved by [CONTACT_12638]. Investigational drugs are stored separately from other drugs in an area of limited access and in accordance with special storage requirements. They are clearly labeled with the identity of the study drug and other control numbers. All drug  accountability,  transfers, recei pts, and disposal are 
recorded i n the Duke Nautilus system . 
 Tetanus compliance and accountability will be managed by [CONTACT_179499].  
10.6 Disposal and Destruction 
 Unused study drugs will be destroyed per Duke Policy and institutional guidelines . 
  
Pro00065241:  AVERT  
Version: [ADDRESS_211122] ELIGIBILITY 
11.1 Inclusion Criteria 
• Age 18- 80 years  
• First or second recurrence of MG (WHO Grade III or IV glioma or astrocytoma) in surgically 
accessible areas with prior histologic diagnosis of MG  
• Bevacizumab- naïve – no prior exposure to Bevacizumab  
• KPS of ≥  70% 
• RT with ≥ 45 Gy tumor dose, completed ≥ 8 weeks prior to study entry 
• Laboratory values must meet the following criteria (using CTCAE v4):  
1) WBC ≥ 2000/uL  
2) Neutrophils ≥ 1500/uL  
3) Platelets ≥ 100x103/uL 
4) Hemoglobin ≥ 9.0 g/dL  
5) Serum creatinine ≤ 1.5x ULN or creatinine clearance (CrCl)≥ 40 mL/min (using the 
Cockcroft -Gault formula)  
a. Female CrCl = (140 - age in years) x weight in kg x 0.85 /72 x serum creatinine in 
mg/dL 
b. Male CrCl = (140 - age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL  
6) AST ≤ 3x ULN  
7) ALT ≤ 3x ULN  
8) Bilirubin≤ [ADDRESS_211123] (except subjects with Gilbert Syndrome, who can have total 
bilirubin < 3.0 mg/dL)  
9) Subjects must have resting baseline O2 saturation by [CONTACT_179500] ≥ 92% at rest. 
• Patients of child bearing potential or with partners of child- bearing potential must agree to 
practice recommended contraceptive methods to prevent pregnancy during treatment and for  [ADDRESS_211124] dose of bevacizumab for subjects receiving bevacizumab as 
stated in the informed consent.  
11.2 Exclusion Criteria 
• Contrast -enhancing tumor component crossing the midline, multi -focal tumor, or tumor 
dissemination (subependymal or leptomeningeal)  
• Clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment  
• Pregnant or need to breast feed during the study period (Negative β -HCG test required), or 
unable to maintain use of contraception while on study  and for [ADDRESS_211125] dose of 
nivolumab 
• Active infection requiring treatment or an unexplained febrile (> 101.5o F) illness  
• Known immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, Hepatitis B or Hepatitis C   
• Known allergy or hypersensitivity to tetanus, or any other tetanus or diphtheria toxoid- containing 
vaccine, or any component of this vaccine (i.e., aluminum phosphate, formaldehyde)  
• Known  severe (Grade 3 or 4) infusion- related allergy or hypersensitivity to any monoclonal 
antibody  
• Previous radiation therapy with anything other than standard radiation therapy (such as previous stereotactic radiosurgery ) or previous treatment with an immune checkpoint inhibitor  (i.e., 
nivolumab, pembrolizumab, ip ilimumab)  
• Unstable or severe intercurrent medical conditions such as severe heart ([LOCATION_001] Association Class 3 or 4) or lung (FEV1 < 50%) disease, uncontrolled diabetes mellitus . 
• Corticosteroid use > 4mg /day at time of consent  
• Prior inguinal lymph node dissection . 
  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 31  
 12 SCREENING AND ON -STUDY TESTS AND PROCEDURES 
Table 2. Screening and On -Study Tests and Procedures  
Prior to Randomization:  
 
1Serum pregnancy testing is required at screening, prior to each leukapheresis, and prior to the first nivolumab infusion.  Ad ditional 
testing can be performed as the treating physician feels is necessary and a urine pregnancy test is allowed at any additional time points.  
2Labs for leukapheresis should be drawn within [ADDRESS_211126] 
DC vaccination. 
13Labs and clinic visit (physical exam, neuro exam, KPS) do not need to be repeated prior to Nivolumab #1 if previously perform ed for 
screening with the same week.  
 
 
 
 
 
  Screening  Leukapheresis #1  Nivolumab IV  
 Cycle 1  Nivolumab IV 
Cycle 2  Nivolumab IV  
Cycle 3  Progression  
Beta HCG  X1 X2 X1,13    
CBC w/diff  X X2 X13 X X  
CMP  X X2 X13 X X  
Ionized Calcium   X2     
LDH  X  X13 X X  
Mg X  X13 X X  
Amylase/Lipase  X  X13 X X  
Thyroid Profile and Free 
T3 X3      
CMV   X4     
Autoimmunity Testing  X5 X5 X13 X5 X5 X5 
Blood for Immunologic 
Monitoring  X4 X6    X7 
MRI  X8     X 
Physical Exam, Neuro 
Exam, KPS, O2 
Saturation9 X  X13 X X  
Con Meds  X  X X X  
Baseline symptoms and 
medical history  X      
AE/SAE monitoring10 X X X X X X 
Tumor Pathology  X11     X11 
MMSE  X      
Nivolumab    X X X  
Randomization      X12  
Pro00065241:  AVERT  
Version: [ADDRESS_211127] -Randomization, Group 1:  
 
 
1Serum pregnancy testing can be performed as the PI [INVESTIGATOR_179459] a urine pregnancy test is allowed.  Serum pregnancy  test is 
required prior to leukapheresis.  
2Labs for leukapheresis should be drawn within [ADDRESS_211128] of 10 yellow top ACD tubes and 1 red top tube.  Immune monitoring will be drawn at Nivolumab cycles 
5, 12, 18 and 21 (or the first cycle of Nivolumab two weeks after vaccine #8 is administered) , and prior to surgery Immune monitoring 
will be drawn at the time of progression, if possible.  After a year, an attempt will be made to obtain blood for immunologic  monitoring [ADDRESS_211129] Duke neuro -oncology visits (10 yellow, 1 red).  
7MRI to be don e prior to cycle 4, before and after surgery per the discretion of the neurosurgeon, and prior to every 4th cycle of 
nivolumab for one year  starting with cycle 12  (i.e., prior to cycles 12, 16, 20, etc.).  Additional MRIs can be performed at the discretion  of 
the treating physician.  If a patient is removed from the study due to clinical progression, a MRI is not required.  
8O2 saturation only required at screening.  O2 saturation will be rechecked at the discretion of the treating physician based on clinica l 
symptoms.  
9Tissue will be collected at the time of surgery.  Tissue may also be obtained at the time of progression at the discretion of  the treating 
physician.  
10Td preconditioning to be administered 12 -24 hours prior to DC vaccine # 3. 
11DC Vaccines to be administered QOW x 3 ( Nivo cycles 8 -10).  Vitals will be checked on the day of the DC vaccine administration at any 
time prior to administration as well as after  DC vaccine administration. 
12DC Vaccines to be administered monthly x 5 (Nivo cycles 12, 14, 16, 18 20).  Vitals will be checked on the day of the DC vaccine 
administration at any time prior to administration as well as after  DC vaccine administration.  
 
  
 
     
Post -Randomization, Group 2:   
Nivolumab QOW  
(Cycles 4 -7) Surgery  Leukapheresis 
#2 Nivolumab QOW  
(Cycles 8 -11) with  
DC Vaccine QOW  
(x 3) Nivolumab QOW 
(Cycles 12 -20) 
with DC Vaccine 
Monthly (x 5) Nivolumab 
QOW  
(Cycles 21+)  Progression  
Beta HCG    X2     
CBC w/diff  X X X2 X X X  
CMP  X X X2 X X X  
Ionized Calcium    X2     
LDH  X   X X X  
Mg X   X X X  
Amylase/Lipase  X   X X X  
Thyroid Profile and Free 
T3 X3   X3 X3 X3  
Autoimmunity Testing  X4 X4 X4 X4 X4 X4 X4 
Blood for Immunologic 
Monitoring  X6 X6 X5 X6 X6  X6 
MRI  X7 X7  X7 X7 X7 X7 
Physical Exam, Neuro 
Exam, KPS, O2 
Saturation8 X   X X X  
Con Meds  X  X X X X  
AE/SAE monitoring  X X X X X X X 
Tumor Pathology   X9     X9 
Nivolumab  X   X X X  
Td Pre -conditioning     X6,10    
DC Vaccine with vitals     X11 X12   
Pro00065241:  AVERT  
Version: [ADDRESS_211130] of 10 yellow top ACD tubes  and 1 red top tube.  Immune monitoring will be drawn prior to surgery, 
prior to vaccines # 1, and 7 , and prior to Nivolumab cycle 17 (or the first cycle of Nivolumab two weeks after vaccine #8 is administered) .  
Immune monitoring will be drawn at the time of progression, if possible.  After a year, an attempt will be made to obtain blood for 
immunologic monitoring [ADDRESS_211131] Duke neuro -oncology visits (10 yellow, 1 red).  
7MRI to be done prior to cycle 4, before and after surgery per the di scretion of the neurosurgeon, and prior to every 4th cycle of 
nivolumab for one year (i.e., prior to cycles 8, 12, 16, 20, etc.).  Additional MRIs can be performed at the discretion of th e treating 
physician.  If a patient is removed from the study due to clinical progression, a MRI is not required.  
8O2 saturation only required at screening.  O2 saturation will be rechecked at the discretion of the treating physician based on clinical 
symptoms.  
9Tissue will be collected at the time of surgery.  Tissue may also be obtained at the time of progression at the discretion of the treating 
physician.  
10Td preconditioning to be administered 12 -24 hours prior to DC vaccine # 3. 
11DC Vaccines to be administered QOW x 3 ( Nivo cycles 5-7).  Vitals will be checked on the day of the DC vaccine administration at any 
time prior to administration as well as after  DC vaccination administration. 
12DC Vaccines to be administered monthly x 5 (Nivo cycles 8, 10, 12, 14 , 16).  Vitals will be checked on the day of the DC vaccine 
administration at any time prior to administration as well as after  DC vaccination administration.  
 
 
     
 
   
Nivolumab  
IV (Cycle 4)  Nivolumab QOW 
(Cycles 5-7) with DC 
Vaccine QOW  Surgery  Leukapheresis #2  Nivolumab QOW  
(Cycles 8 -15) with  
DC Vaccine 
Monthly (x 5) Nivolumab 
QOW  
 (Cycles 16+)  Progression  
Beta HCG  X1 X1  X2 X1 X1  
CBC w/diff  X X X X2 X X  
CMP  X X X X2 X X  
Ionized Calcium     X2    
LDH  X X   X X  
Mg X X   X X  
Amylase/Lipase  X X   X X  
Thyroid Profile and Free 
T3 X3 X3   X3 X3  
Autoimmunity Testing  X4 X4 X4 X4 X4 X4 X4 
Blood for Immunologic 
Monitoring   X6 X6 X5 X6 X6 X6 
MRI  X7  X7  X7 X7 X7 
Physical Exam, Neuro 
Exam, KPS, O2 
Saturation8 X X   X X  
Con Meds  X X  X X X  
AE/SAE monitoring  X X X X X X X 
Tumor Pathology    X9    X9 
Nivolumab  X X   X X  
Td Pre -conditioning   X6,10      
DC Vaccine with vitals   X11   X12   
Pro00065241:  AVERT  
Version: [ADDRESS_211132] is considered a screen failure prior to vaccine treatment, the source documents for electronic data 
entry will be stored in a locked cabinet in a locked room in the PRTBTC Offices . 
 
CBC w/diff, complete metabolic panel, magnesium, LDH, amylase, lipase, thyroid profile, free T3, and beta HCG (if necessary) will be drawn at screening.  The serum CMV screen (1 red top tube) will be 
drawn prior to the [ADDRESS_211133] will be performed. These tests may be batched tested and results delayed. 
 Initial clinical evaluations will also include a baseline MMSE.  
 A baseline MRI  of the brain  (with and without gadolinium enhancement) will be obtained as per standard 
of care. 
 
After patients have been consented, they will be entered into the Velos eResearch system . 
12.[ADDRESS_211134] blood samples taken for the following tests as 
required by [CONTACT_34548]: CBC  w/diff, CMP, ionized Calcium, and β -HCG (for females of 
child-bearing potential). Total estimated blood volume required for these evaluations is 12- [ADDRESS_211135] of care vaccination with 0.5 mL of Td (tetanus and 
diphtheria toxoids adsorbed) I.M. into the deltoid muscle to ensure adequate immunity to the tetanus 
antigen.  Each subject will initially return every 2 weeks and receive nivolumab 3 mg/kg IV while the DC 
vaccines are being prepared from the initial le ukapheresis  and then randomized to two treatment arms 
(Group I and Group II) .  Peripheral blood will be drawn for immune monitoring prior to treatment with the 
5
th cycle  of nivolumab ( second post -randomization infusion of nivolumab) .  Group I will receive nivolumab 
alone I.V. every 2 weeks x approximately 8 weeks and Group II will receive the 4th cycle of nivolumab 
then receive nivolumab 3 mg/kg IV every [ADDRESS_211136]  DC vaccine, patients  from both groups  will receive vaccine site pre- conditioning.  A single dose of 
Td toxoid ( 1 flocculation unit, Lf, in 0. 4 mLs) will be administered to a single side of the groin 12- [ADDRESS_211137]  DC vaccine, which is always given bilaterally at the groin site.  At the vaccine # 3 visit, 
prior to vaccine # [ADDRESS_211138] will resume nivolumab 3mg/kg IV every 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 35  
 two weeks along with DC vaccine administrations as described in section 7.1 (Group I and Group II differ)  
for a total of 8 vaccines or until progression (whichever comes first). Nivolumab will  continue until 
progression .  See section 12.7.[ADDRESS_211139] common manifestations of autoimmunity seen in related 
trials [104-108] have included enterocolitis, dermatitis, uveitis, hepatitis, and hypophysitis . 
 
12.2.1  Rationale for Continued Treatment in Cases of Suspected Progressive Disease  
Accumulating clinical evidence indicates some subjects treated with immune system stimulating agents may develop progression of disease (by [CONTACT_121021]) before demonstrating clinical objective responses and/or stable disease. This phenomenon was observed in approximately 10% of subjects in the Phase 1 study of nivolumab[ 109]. Two hypotheses have been put forth to explain this 
phenomenon.  First, enhanced inflammation within tumors could lead to an increase in tumor size which 
would appear as enlarged index lesions and as newly visible small non- index lesions. Over time, both the 
malignant and inflammatory portions of the mass may then decrease leading to overt signs of clinical improvement. Alternatively, in some individuals, the kinetics of tumor growth may  initially outpace anti -
tumor immune activity. With sufficient time, the anti- tumor activity will dominate and become clinically 
apparent. Therefore, subjects initially meeting radiologic criteria for disease progression (see Section 
12.1) will be allowed to continue study therapy until a second radiologic confirmation of progression performed approximately 8 weeks later as long as the following criteria are met: 1) the subjec t 
experiences investigator -assessed clinical benefit (i.e., no new clinical symptoms  contributed to disease 
progression) and 2) the subject is tolerating the study treatment  (i.e., no expected toxicities higher than 
grade 3 [with the exception of Grade 2 u veitis – see Section 12.2.2 below] or unexpected toxicities) . 
 Any evidence of tumor response will be determined according to the Duke PRTBTC SOP (see APPENDICES). RANO criteria [110] will be used for assessment of pseudoprogression. Tumor 
progression will need to be documented histologically, unless there are clinical contraindications, to exclude inflammatory responses presenting as radiographic or clinical changes, which could indicate potentially toxic or therapeutic responses and not tumor progression. Patients will be followed until death.  
 Standard treatment for glioblastomas (including radiation therapy and temozolomide) may result in a transient increase in tumor enhancement (pseudoprogression) in a subset of subjects that eventually subsides without any change in therapy. Pseudoprogression may be difficult to differentiate from true tumor progression and may have important implications for patient management.  A ccumulating evidence 
also indicates that some s ubjects treated with immune system stimulating agents may also develop 
apparent progression of disease (by [CONTACT_121021]) before demonstrating clinical objective responses and/or stable disease[ 109].   This phenomenon was observed in approximately 10% 
of subjects in the Phase 1 study of nivolumab and has also been reported for ipi[INVESTIGATOR_79285] [111].  
 
In order to minimize premature discontinuation of study medication and distinguish pseudoprogression 
from progressive disease, subjects initially meeting radiologic criteria for disease progression may continue receiving study medication until confirmation of progression with an MRI performed approximately [ADDRESS_211140] be met:  
1. The subject is believed to demonstrate clinical benefit as determined by [CONTACT_093] . 
2. The subject is tolerating study medication. 
 Subjects with confirmed progression (approximately 8 weeks after initially assessed progression) will discontinue study medication and enter the follow up/survival phase of the study. If progression is confirmed, then the date of disease progression will be the first date the subject met the criteria for 
progression.  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 36  
 12.2.2  Discontinuation Criteria  for Nivolumab  
• Any Grade 2 drug- related uveitis  or eye pain or blurred vision  that does  not respond to 
topi[INVESTIGATOR_179460] 1 severity  within  the re-treatment  period OR 
requires systemic treatment.  
• Any Grade 3 non-skin, drug- related adverse  event  lasting  > 7 days,  with the following  
exceptions  for drug-related laboratory  abnormalities : uveitis,  pneumonitis,  bronchospasm,  
diarrhea, colitis, neurologic toxicity,  hypersensitivity  reactions, and infusion reactions:  
- Grade 3 drug- related uveitis,  pneumonitis,  bronchospasm,  diarrhea,  colitis,  neurologic  
toxicity,  hypersensitivity  reaction,  or infusion  reaction of any duration requires  
discontinuation.  
- Grade 3 drug- related laboratory  abnormalities  do not require treatment  discontinuation 
except:  
♦ Grade 3 drug- related thrombocytopenia > 7 days  or associated with bleeding requires  
discontinuation.  
♦ Any drug- related liver function test  (LFT)  abnormality  that  meets  the  following  criteria 
require discontinuation:  
o AST or ALT > [ADDRESS_211141] 
o Total bilirubin > [ADDRESS_211142] or ALT > [ADDRESS_211143]  and total bilirubin > [ADDRESS_211144].  
• Any Grade 4 drug- related adverse  event  or laboratory  abnormality,  except  for the following  
events  which  do not require  discontinuation:  
- Grade 4 amylase or lipase abnormalities that are not associated  with symptoms  or clinical 
manifestations  of pancreatitis.  It is recommended to consult with the PI [INVESTIGATOR_179461] 4 amylase or lipase abnormalities.  
- Isolated Grade 4 electrolyte  imbalances/abnormalities that are not associated with clinical  
sequelae and are  corrected with supplementation/appropriate management within  72 hours of 
their onset.  
• An y  dosing interruption lasting > [ADDRESS_211145] dose with the following exceptions:  
- Dosing interruptions to allow for prolonged steroid tapers  to manage drug- related adverse 
events  are allowed.  Prior to re -initiating treatment in a subject with a dosing interruption 
lasting > [ADDRESS_211146] be consulted.  Tumor assessments  
should continue as  per protocol  even  if dosing is  interrupted.  
- Dosing interruptions > [ADDRESS_211147]  with a dosing interruption lasting > [ADDRESS_211148]  be 
consulted.  Tumor assessments should continue as per protocol even if  dosing is  
interrupted.  
• Any adverse event,  laboratory  abnormality,  or intercurrent  illness  which,  in the judgment  of the 
Investigator,  presents  a substantial  clinical risk to the subject  with continued nivolumab and 
DC dosing. 
 
12.2.[ADDRESS_211149] with fever, chills, rigors, headache, rash, pruritus, arthralgias, hypo- or hypertension, 
bronchospasm, or other symptoms. All Grade 3 or 4 infusion reactions should be reported within 24 hours to the PI [INVESTIGATOR_45781]. Infusion reactions should be graded according to NCI 
CTCAE (version 4) guidelines.  
 Treatment recommendations are provided below and may be modified based on local treatment standards and guidelines as appropriate:  
 
For Grade 1 symptoms : (Mild reaction; infusion interruption not indicated; intervention not indicated)  
Pro00065241:  AVERT  
Version: [ADDRESS_211150] until recovery from symptoms. The following prophylactic 
premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or 
paracetamol 325 to 1000 mg (acetaminophen) at least 30 minutes before additional nivolumab 
administrations.  
 
For Grade 2 symptoms : (Moderate reaction requires therapy or infusion interruption but responds 
promptly to symptomatic treatment [e.g. , antihistamines, non- steroidal anti -inflammatory drugs, narcotics, 
corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated for ≤ 24 hours).  
 
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen); remain at bedside and monitor subject until resolution of symptoms. Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the infusion is interrupted, then restart the infusion at 50% of the original infusion rate when symptoms resolve; if no further complications ensue after 30 minutes, the rate 
may be increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur then no 
further nivolumab will be administered at that visit. Administer diphenhydramine [ADDRESS_211151] be recorded on the case report form (CRF). The following prophylactic pre- medications are recommended 
for future infusions: diphenhydramine 50 mg (or  equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen) should be administered at least 30 minutes before additional nivolumab administrations. 
If necessary, corticosteroids (recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be 
used. 
 
For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [i .e., not rapi[INVESTIGATOR_86025]/or brief interruption of infusion]; recurrence of symptoms following initial improvement; hospi[INVESTIGATOR_14138] [e.g. , renal impairment, pulmonary 
infiltrates]). Grade 4: (life- threatening; pressor or ventilatory support indicated).  
 
Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline, and treat the subject as  follows. Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of  a 1:1,000 solution for 
subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly for IV administration, 
and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg IV (or equivalent), as needed. Subject 
should be monitored until the investigator is comfortable that the symptoms will not recur. Nivolumab will be permanently discontinued. Investigators should follow their institutional guidelines for the treatment of  
anaphylaxis. Remain at bedside and monitor subject until recovery from symptoms. In the case of late-occurring hypersensitivity symptoms (e.g. , appearance of a localized or generalized pruritus within 1 
week after treatment),  symptomatic treatment may be given (e .g., oral antihistamine, or corticosteroids).  
12.[ADDRESS_211152] been administered, the treatment 
phase of the study will be over and the follow -up period will begin.   Please see Section 12.2.1 above for 
details in treating subjects beyond suspected progression.  
12.4 Follow-up Period 
 All patients will be followed for survival and data recorded by [CONTACT_3476] . 
12.5 End of Study 
 Rationale for taking a patient off study will be documented (see section 12.2.2). All patients will be followed for survival and recorded by [CONTACT_3476] . 
Pro00065241:  AVERT  
Version: [ADDRESS_211153](s) 
12.6.[ADDRESS_211154] from 
the study at any time based on his/her discretion. Reasons for PI -initiated withdrawal may include, but are 
not limited to the following:  
• Patients with an active infection requiring treatment or having an unexplained febrile i llness 
(Tmax > 99.5 F).  
• Adverse events  
• Abnormal laboratory values  
• Unacceptable toxicity (see section 9.1.1) . If a subject discontinues from one study drug 
(nivolumab or DC vaccine)  due to unacceptable toxicity attributed to that  study drug, the subject 
can continue on the other study drug  at the discretion of the investigator . If in the investigator’s 
opi[INVESTIGATOR_179462], the investigator can hold both study drugs.  
• Protocol deviation  
• Administrative issues  
• Disease progression  
• Pregnancy  
• Clinical indications for surgical resection prior to treatment plan. 
 
12.6.2  Follow -up Requirements for Early  Withdrawal  
 
Subjects that received any nivolumab and/or vaccine therapy will be assessed and followed for serious 
adverse event monitoring/safety analysis for [ADDRESS_211155] infusion and/or vaccine (please 
see section 15.1 for safety analyses of the lead- in phase) . 
12.6.3  Replacement of Early  Withdrawal (s) 
 Patients who terminate protocol treatment without experiencing an unacceptable adverse event or 
completing [ADDRESS_211156] and/or family at the 
screening visit and reviewed at each study visit. This data may include the following:  
• All past medical and surgical history  
• Current medications  
• Changes in physical or neurologic symptoms  
• Any adverse events . 
12.7.2  Physical Exam  
 
Vital signs and physical and neurologic examinations will be assessed and recorded along with a KPS 
score prior to enrollment and at each visit.  Vital signs will also be assessed prior to nivolumab and DC 
vaccines.  Lastly, vital signs will also be assessed after DC vaccine administration .   
 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 39  
 12.7.3  Immunologic Assessments  
Blood for serum CMV screen ( 1 red top tube) will be drawn prior to the 1st leukapheresis . Immunological 
response evaluations for baseline values will be conducted on the leukapheresis sample used to 
generate the DCs and on the second leukapheresis sample as well as from 1 red top tube done prior to each leukapheresis.  Peripheral blood drawn for immunologic monitoring (10 yellow and 1 red top tubes) will be drawn  before surgery, before the fifth nivolumab infusion, a nd at progression (if feasible) in BOTH 
groups.  Group I will have blood drawn prior to the [ADDRESS_211157] the blood drawn prior to the 7th vaccine. The total amount of blood required for 10 yellow/1 red top 
tubes  will be about 100 mLs. Plasma from the yellow top tubes will be collected at each time point listed 
where immunologic monitoring is done.  Lastly, 10 yellow/[ADDRESS_211158] vaccine (#8) at the next clinic visit prior to infusion of nivolumab monotherapy  in 
both groups . After a year, an attempt will be made to obtain blood for immunologic monitoring 2- [ADDRESS_211159] Duke neuro- oncology visits (10 yellow  and 1 red top tubes ). 
12.7.4  Correlative Assessments  
 Testing will be performed by 'optimal batch testing'  in  which  samples  will be  thawed,  rested  overnight,  and tested according to established/validated SOPs on file at Duke. All samples from each study participant will be analyzed together.  The antigen to be tested will be pp65  with the CEF peptide and 
mitogen controls.  
 
The proportion of specific lymphocyte subsets and expression levels of T cell co- stimulatory markers in 
PBMC preparations and TILS will be quantified by [CONTACT_4133]. Analyses may include, but not 
necessarily be limited to, the proportion of T, B, and NK cells, granulocytes, the proportion of memory and effector T cell subsets, and expression levels of PD -1, PD -L1, other B7 family members, ICOS, and Ki67.  
 
Fresh tumor tissue will be collected and frozen for gene expression and T cell receptor sequencing.  The 
expression level of genes in TILs and whole blood samples that are associated with response to 
nivolumab will be assessed by [CONTACT_179501]/or quantitative RT -
PCR analysis. Analysis may include, but will not  necessarily be limited to, genes associated with immune-
related pathways, such as T cell activation, antigen processing and presentation, and apoptosis . 
 
As samples permit but not limited to soluble factors, such as cytokines, chemokines, soluble receptors, 
and antibodies to tumor antigens , will be characterized and quantified by [CONTACT_61884]. 
Analyses may include, but will not necessarily be limited to, soluble CD25, soluble PD -1, soluble LAG -3, 
CCL3 , and  CXCL -9. Collected serum samples will also be used for the assessment of tumor antigen-
specific responses elicited following treatment with and the combination therapy to explore which 
antitumor antibodies are most associated with clinical response.  
 
[ADDRESS_211160] receiving study drug (for purposes of this study, this is defined as nivolu mab or DC vaccine) which does not necessarily have a causal relationship wit h 
this treatment. For this protocol, the definition of AE also includes worsening of any pre- existing medical 
condition. An AE can therefore be any unfavorable and unintended or worsening sign (including an 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 40  
 abnormal laboratory finding), symptom, or disease temporally associated with the use of the nivolumab 
and/or DC vaccines, whether or not related. A ll abnormal laboratory findings that can be graded by [CONTACT_179502] 4.[ADDRESS_211161] signs consent  through the End of Study visit (as defined in Section 12.6), all 
AEs must be recorded in the subject medical record and adverse events case report form.  All SAEs will  
be recorded from the time consent is signed until [ADDRESS_211162] for an AE, the 
severity of the AE will be graded as mild (1), moderate (2), severe (3), life- threatening (4), or fatal (5).  
 Attribution of AEs will be indicated as follows:  
- Definite:  The AE is clearly related to the study drug  
- Probably:  The AE is likely related to the study drug  
- Possible:  The AE may be related to the study drug 
- Unlikely:  The AE is doubtfully related to the study drug 
-            Unrelated: The AE is clearly NOT related to the study drug.  
13.1.1  Reporting of AEs  
 A summary of all adverse events (not just those considered related to the study drugs ) will be kept which 
will categorize the event by [CONTACT_34565], relationship to which treatment, its grade of severity, and resolution. Periodic review by [CONTACT_978] [INVESTIGATOR_179463]. If any such trends are identified, depending on their severity and frequency, a protocol amendment will be considered. 
13.2 Serious Adverse Events  
 An AE is considered “serious” if in the opi[INVESTIGATOR_179464] (nivolumab and DC vaccine) : 
 
- Fatal  
- Life-threatening  
- Constitutes a congenital anomaly or birth defect  
- A medically significant condition (defined as an event that compromises subject safety or may require medical or surgical intervention to prevent one of the three outcomes above).  
- Requires inpatient hospi[INVESTIGATOR_1081]  
- Results in persistent or significant incapacity or substantial disruption to conduct normal life functions.  
13.2.1  Reporting of SAEs  
 All SAEs that are thought to be possibly, probably, or definitely related to study treatment  (including 
leukapheresis)  should be reported immediately to [CONTACT_179517]  (Pager:  [PHONE_3853]) or her 
designee (919- 684-8111) and to the FDA. Fatal or life- threatening, unexpected adverse events will be 
reported to the FDA by [CONTACT_756], facsimile, or in writing as soon as possible, but no later than [ADDRESS_211163] be reported to BMS Worldwide Safety.  The sponsor/investigator will be 
required to reconcile SAEs reported in the clinical database with SAE cases transmitted to BMS Global 
Pharmacovigilance (GPV&E); worldwide.safety@bms . BMS requests this is initiated by [CONTACT_179503]00065241:  AVERT  
Version: [ADDRESS_211164] be sent 
to [EMAIL_176].    
 
Potential drug induced liver injury (DILI) is also considered an important medical event . Wherever 
possible, timely confirmation of initial liver -related laboratory abnormalities should occur prior to the 
reporting of a potential DILI event.  All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs . Potential drug induced liver injury is defined as:  
1. ALT or AST elevation > 3 times upper limit of normal (ULN)  
AND  
2. Total bilirubin > [ADDRESS_211165], without initial findings of cholestasis (elevated serum alkaline phosphatase)  
AND  
No other immediately apparent possible causes of AST/ALT elevation and hyperbilirubinemia, including, 
but not limited to, viral hepatitis, pre- existing chronic or acute liver disease, or the administration of other 
drug(s) known to be hepatotoxic.  
 
Any overdose or pregnancy is considered a SAE regardless of CTCAE grade level and will be documented and reported.  
  
All adverse events that are considered serious, unanticipated, and related or possibly related to the 
research (as defined by 21CRF312.32[a]) will be reported to the Duke University Medical Center IRB and FDA using the appropriate SAE reporting process. At the time of the annual progress report to the Duke 
University Medical Center IRB and the FDA, a summary of the overall toxicity experience will be provided, including SAEs that are felt to be unlikely or unrelated to study treatment . 
13.3 Safety Oversight Committee (SOC) 
 The DCI SOC is responsible for annual data and safety monitoring of DUHS sponsor -investigator phase I 
and II, therapeutic interventional studies that do not have an independent DSMB. The primary focus of the SOC is review of safety data, toxicities and new information that may affect subject safety or efficacy. Annual safety reviews include but may not be limited to review of safety data, enrollment status, stoppi[INVESTIGATOR_179465], accrual, toxicities, reference literature, and interim analyses as provided by [CONTACT_103] -investigator. The SOC in concert with the DCI Monitoring Team (see Section 14.1 for Monitoring 
Team description) oversees the conduct of DUHS cancer -related, sponsor -investigator therapeutic 
intervention and prevention intervention studies that do not have an external monitoring plan, ensuring 
subject safety and that the protocol is conducted, recorded and reported in accordance with the protocol, SOPs, GCP, and applicable regulatory requirements . 
 
13.[ADDRESS_211166] (DSMB) 
 The Principal Investigator [INVESTIGATOR_34511]- Investigators must comply with applicable federal, state, and local 
regulations regarding reporting and disclosure of conflict of interest. Conflicts of interest may arise from situations in which financial or other personal considerations have the potential to compromise or bias 
professional judgment and objectivity. Conflicts of interest include but are not limited to royalty or 
consulting fees, speaking honoraria, advisory board appointments, publicly -traded or privately -held 
equit ies, stock options, intellectual property, and gifts.  
 The Duke University School of Medicine’s RIO reviews and manages research- related conflicts of 
interest. The Principal Investigator [INVESTIGATOR_34511]- Investigators must report conflicts of interest annually and 
within [ADDRESS_211167] a documented management plan that is developed in conjunction with the Duke RIO and approved by [CONTACT_1201]/IEC.  
 
Pro00065241:  AVERT  
Version: [ADDRESS_211168] (DSMBplus)  has been  established.  Please see Appendix  – Section 18.[ADDRESS_211169] is enrolled, followed by [CONTACT_12636] 1 – 3 subjects until the study is closed to enrollment 
and subjects are no longer receiving study interventions that are more than minimal risk.   
 Additional monitoring may be prompted by [CONTACT_12637], unexpected frequency of serious and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI leadership, the DCI Cancer Protocol Committee, the SOC, the sponsor, the Principal Investigator, or 
the IRB.  All study documents must be made available upon request to the DCI Monitoring Team and 
other authorized regulatory authorities, including but not limited to the National Institute of Health, National Cancer Institute, and the FDA.  Every reasonable effort will be made to maintain confidentiality during study monitoring.  
 
14.[ADDRESS_211170] audits to evaluate compliance with the protocol and the principles of GCP.  The PI [INVESTIGATOR_33573](s)  direct access to all relevant 
documents and to allocate his/her time and the time of the study team to the CTQA auditor( s) in order to 
discuss findings and any relevant issues.  
 
CTQA audits are designed to protect the rights and well -being of human research subjects. CTQA audits 
may be routine or directed (for cause). Routine audits are selected based upon risk metrics generally 
geared towards high subject enrollment, studies with limited oversight or monitoring, Investigator initiated Investigational Drugs or Devices, federally -funded studies, high degree of risk (based upon adverse 
events, type of study, or vulnerable populations), Phase I studies, or studies that involve Medicare populations. Directed audits occur at the directive of the IRB or an authorized Institutional Official.  
 CTQA audits examine research studies/clinical trials methodology, processes and systems to assess whether the research is conducted according to the protocol approved by [CONTACT_12638]. The primary purpose of the audit/review is to verify that the standards for safety of human subjects in clinical trials and the quality of data produced by [CONTACT_12639]. The audit/review will serve as a quality 
assurance measure, internal to the institution. Additional goals of such audits are to detect both random 
and systemic errors occurring during the conduct of clinical research and to emphasize “best practices” in the research/clinical trials environment.  
14.3 Data Management and Processing 
14.3.1  Study Documentation  
 Study documentation includes but is not limited to source documents, case report forms, monitoring logs, 
appointment schedules, study team correspondence with sponsors or regulatory bodies/committees, and 
regulatory documents that can be found in the DCI -mandated “Regulatory Binder”, which includes but is 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 43  
 not limited to signed protocol and amendments, approved and signed informed consent  forms, FDA Form 
1572, CAP and CLIA laboratory certifications, and clinical supplies receipts and distribution records.  
 
Source documents are original records that contain source data, which is all information in original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source documents include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or  evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_164372], microfiches, photographic negatives, microfilm or 
magnetic media, x -rays, subject  files, and records kept at the pharmacy, at the laboratories and at 
medico- technical departments involved in the clinical trial.  When possible, the original record should be 
retained as the source document.  However, a photocopy is acceptable provided that it is a clear, legible, and an exact duplication of the original document.  
14.3.2  Case Report Forms (CRFs)  
 The subject’s medical records will be the primary source document for the study. Source documents include all information in original records and certified copi[INVESTIGATOR_34504], 
observations, or other activities in a clinical investigation used for reconstructing and evaluating the investigation.
1 Source documentations may also include paper eligibility checklists, data fl owsheets, 
patient reported outcomes and other paper documents. The PI, study coordinator, study research nurse, 
data management team and all associated study key personnel, are permitted to make entries, changes, 
or corrections in the source documents or database per the study delegation of authority log.  
 Errors on the source documents will be crossed out with a single line, and this line will not obscure the original entry. Changes or corrections will be dated, signed, initialed, and explained (if necessary). 
Database changes will be tracked via electronic trail automatically . 
14.3.3  Data Management Procedures and Data Verification  
 
The DCI IT Shared Resource has developed Title 21 CFR Part 11 compliant databases for cancer clinical trials. DCI IT has extensive expertise in database quality assurance, data standards, and use of caBIG tools to support cancer researchers.  
 Data queries will be generated automatically by [CONTACT_1624]. These data queries signify the presence of data inconsistencies. The study and data management team will cross -reference the data to 
verify accuracy. Missing or implausible data will be highlighted for the PI [INVESTIGATOR_12598] (i.e., confirmation of data, correction of data, completion or confirmation that data is not available, etc.).  
 
The database will be reviewed and discussed prior to database closure, and will be closed only after 
resolution of all remaining queries.  An audit trail will be kept of all subsequent changes to the data.  
14.3.4  Coding 
 All medical terms will b e coded using CTCAE (version 4).  
14.3.5  Study Closure  
 
                                                      
1 In 21 CFR 312.62(b), reference is made to records that are part of case histories as “supporting data;” the 
ICH guidance for industry E6 Good Clinical Practice: Consolidated Guidance (the ICH E6 guidance) 
(available at 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm)  uses 
the term “source data/documents.” For the purpose of this guidance, these terms describe the same information and have been used interchangeably.  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 44  
 Following completion of the studies, the PI [INVESTIGATOR_12599]:  
 
- Data clarification and/or resolution  
- Accounting, reconciliation, and destruction/return of used and unused study drugs  
- Review of site study records for completeness  
- Shipment of all remaining laboratory samples to the designated laboratories . 
  
Pro00065241:  AVERT  
Version: [ADDRESS_211171] be approved by [CONTACT_12641].  
 Patients will be randomized to one of two treatment arms  – Group I and Group II.  In Group I, patients will 
receive nivolumab every [ADDRESS_211172] DCs or PBLs that 
meet release criteria.  A patient within G roup I who withdraws from protocol treatment after surgery will be 
included in the correlative analyses if the DC vaccine met the release criteria whether or not it was administered.  
15.2 Patient Demographics and Other Baseline Characteristics  
 The socio- demographic and clinical characteristics of subjects randomized to each of the two treatment 
arms  will be summarized using descriptive statistics (e.g. means/standard deviations/percentiles or 
frequencies).   
15.[ADDRESS_211173] or second recurrent, resectable WHO Grade III 
and IV malignant gliomas.  
15.4.1  Variable  
To assess the safety of the combination of DC vaccination and  nivolumab, the percentage of patients who 
experience unacceptable toxicity during combination treatment (i.e. DC vaccination + nivolumab)  will be 
tabulated.   
 Unacceptable toxicity is defined in Section 9.1.1.  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 46  
 15.4.2  Statistical Hypothesis, Model, and Method of Analysis  
[IP_ADDRESS]  Statistical Hypothesis, Model, and Method of Analysis  
As described in section 15.8, the goal of the study is to determine whether the addition of the DC vaccine 
to nivolumab treatment increases the prevalence of unacceptable toxicity.  Topalian et al .[112] reports 
that 14% (approximate 95% confidence interval:  10%, 18%)  of patients treated with nivolumab alone 
experienced a grade 3 or 4 adverse event.  If the true unacceptable toxicity rate with the combination 
treatment is approximately 10%, then the treatment is considered safe.  However, if the true unacceptable toxicity rate is 35% or greater, the treatment combination as prescribed in this protocol is not safe.  A one-sample binomial test will be used to differentiate between an unacceptable toxicity rate of 10% and 35%.   
Further details are provided in section 15.7.  In addition, a 90% exact binomial confidence interval for the 
unacceptable toxicity rate will be generated.  
[IP_ADDRESS]  Related Statistical Analyses  
Adverse events experienced by [CONTACT_179504] (nivolumab + DC vaccine)  
will also be summarized in several  other forms to satisfy scientific and monitoring needs, as well as 
various regulatory reporting needs (e.g. FDA, DCI SOC, and ClinicalTrials.gov):  
 
• Among all patients who receive any combination protocol treatment, the frequency of adverse 
events that are possibly, probably, or definitely related to protocol treatment will be tabulated by 
[CONTACT_179505].  
 
• Among all patients who receive any combination protocol treatment, the frequency of adverse 
events regardless of attribution will be tabulated by [CONTACT_179505].  
 
• Among patients who terminate combination treatment due to an unacceptable toxicity or receive 
at least 3 vaccinations, the frequency of adverse events that are possibly, probably, or definitely 
related to protocol treatment during the 8 vaccinations will be tabulated by [CONTACT_179505].    
 
• Among patients who terminate combination treatment due to an unacceptable toxicity or receive 
at least 3 vacci nations, the frequency of adverse events regardless of attribution to protocol 
treatment during the 8 vaccinations will be tabulated by [CONTACT_179506].  
 
Given that nivolumab remains an investigational agent too, there will  be a need to summarize adverse 
events experienced during the period of time when nivolumab is administered alone. Tabulations that 
summarize all adverse events as well as tabulations that summarize those that are possibly, probably, or 
definitely related to nivolumab treatment will be generated.  
15.4.3  Handling of Missing Values, Censoring, and D iscontinuations  
If a patient terminates protocol treatment without experiencing an unacceptable toxicity and without 
receiving 3 vaccinations, the patient will be replaced for the primary analyses . 
15.5 Secondary Objective  
 The secondary objective of this study is to describe the survival and PFS of subjects treated with any 
protocol treatment (i.e. nivolumab or DC vaccines) .  Survival is defined as the time between first initiation 
of nivolumab treatment  and death, or last follow -up if the patient remains alive.  PFS is defined as the 
time between treatment initiation and initial progression or death, or date of last follow -up if the patient 
remains alive without disease progression.  The Kaplan- Meier estimator will be used to describe the OS 
and PFS experience of all patients.  Median OS and PFS will also be calculated.  Patients who are not 
able to tolerate nivolumab and are removed from the study will not be included in these analyses.  Patients for whom DC vaccines cannot be manufactured will not be included in the survival analyses.  
Pro00065241:  AVERT  
Version: [ADDRESS_211174] clinically meaningful differences.  Additional descriptive analyses may also be 
conducted, including an examination of OS/PFS from resection.  
15.[ADDRESS_211175] DCs or PBLs that meet release criteria.   
15.6.1  Exploratory Objective  #1:  Immunologic Response to pp65  
Within each group, changes between baseline and a pre- resection assessment for various  measures of 
immune response derived from PBMC  plasma/serum will be described.  When appropriate, these 
descriptive statistics may include mean and standard deviation, or medians and quantiles.   
 Within each group, a paired t -test will be conducted to assess the impact of nivolumab (Group I ) or 
nivolomab with DC vaccination (Group II) on these changes in immune function.  Assuming normality is 
not appropriate, a Wilcoxon signed- rank test will be conducted. 
 Analysis of covariance will be used to compare treatment groups with respect to change, with the 
baseline measure serving as a covariate.  If normality is not an appropriate assumption,  a Wilcoxon rank 
sum test will compare treatment groups with respect to the change in the various measur es of immune 
response that are of interest.  
15.6.2  Exploratory Objectives  #2: T -cell Costimulatory M arkers  
Analyses similar to those described in section 15.6.[ADDRESS_211176] of nivolumab 
and DC vaccination on T- cell costimulatory markers.  
15.6.3  Exploratory Objectives  #3: Cytokines and Other S oluble F actors  
Analyses similar to those described in section 15.6.[ADDRESS_211177] of nivolumab 
and DC vaccination on cytokines and other soluble f actors.  
15.6.4  Exploratory Objectives  #4: Gene E xpression  
Gene expression will be measured in PBMC samples collected serially from patients, as well as from resected tumor.  Analyses similar to those described in section 15.6.[ADDRESS_211178] to gene expression as measured within tumors.  
15.6.5  Exploratory Objectives  #5: Epi[INVESTIGATOR_179466] -PD-[ADDRESS_211179] -treatment 
collection of PBMCs, TCR repertoires of PBLs (pre- and post -treatment) will be assessed. The post -
treatment  collection occurs before resection.  For each sample, we will compute the total number of 
unique clones. Within each group, a comparison of TCR repertoires pre- and post -treatment is of interest.  
To test whether the paired samples have different variances with respect to the number of unique TCR clones, the Fligner -Killeen median test for homogeneity of variance will be used. This test is robust 
against departures from normality. To assess the distribution of T cell clonal frequency, Shannon’s entropy normalized by [CONTACT_26500]2  (# of TCR unique clones) will be computed. Wilcoxon signed- rank test will 
compare the paired measures of entropy. The proportion of TCR overlap between matched specimens 
Pro00065241:  AVERT  
Version: [ADDRESS_211180]-treatment measures of entropy for PBLs.  
 The TCR repertoire of TILs obtained from the resection tissue will be assessed, and Shannon’s entropy will be computed as described above.  Wilcoxon rank sum test will be used to compare groups with respect to post -treatment measures of entropy for TILs.    
15.7 Interim Safety  Analysis 
Rigorous monitoring of toxicities in a manner similar to that found in many Phase I dose- escalation 
studies would require accrual suspension between stages of patient accrual while relevant data matures. Accrual will not be suspended to formally assess the toxicity profile unless the following guidelines are satisfied. Rather, the study  will be monitored continuously for the occurrence of unacceptable adverse 
events, with the primary focus being on adverse events occurring during  combination treatment (i.e. DC 
vaccination + nivolumab) .  Included in these analyses are patients who have completed at least [ADDRESS_211181] year, and then every 6- 12 months thereafter . 
 
Tabulated below are the conditions under which accrual will be temporarily suspended and data carefully 
reviewed to determine the appropriate action, including permanent study termination, continuation with patient accrual after appropriate amendment (including possibly a change in monitoring rules), or continuation with patient accrual with no modification of the protocol. Accrual will also be suspended whenever a death occurs that is possibly, probably, or definitely related to treatment with vaccine and nivolumab.  
 
Table 3. Conditions for Temporary Accrual Suspension 
Number of patients who 
have received 3 DC 
vaccinations or 
experienced an unacceptable adverse event during combination 
treatment  Number of 
patients with unacceptable toxicity requiring accrual suspension  
6-7 ≥3 
8-10 ≥4 
11-14 ≥5 
15-20 ≥6 
21-24 ≥7 
≥25 ≥[ADDRESS_211182] not been adjusted for differential length of follow -up of accrued patients. The 
probability of accrual suspension as a function of the true unacceptable toxicity rate is tabulated below based upon simulation studies. These statistics were generated assuming toxicity outcome was known at the time of accrual, and ignored issues such as time to toxicity, accrual rate, and length of follow -up. 
 
Table 4 . Probability of Accrual Suspension as a Function of the True Unacceptable Toxicity Rate  
Underlying 
unacceptable 
toxicity rate  Probability of 
accrual 
suspension  Expected # of 
Patients  
0.01 <0.0001  30 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 49  
 0.05 0.004  29.9 
0.1 0.039  29.1 
0.15 0.15 27.4 
0.2 0.35 24.2 
0.25 0.58 20.6 
0.3 0.79 16.5 
0.35 0.91 13.1 
0.4 0.97 10.7 
0.45 0.99 9.0 
0.5 >0.99  7.9 
 
Patients who terminate combination protocol treatment without experiencing an unacceptable toxicity  
during combination treatment  and without receiving 3 vaccinations will be replaced for the evaluation of 
the primary endpoint.  
15.8 Sample Size Calculation  
 Topalian, et al., [112] reports that 14% (approximate 95% confidence interval:  10%, 18%) of patients 
treated with nivolumab alone experienced a grade 3 or 4 adverse event. If the true unacceptable toxicity rate with the combination treatment is approximately 10%, then the treatment is considered safe.  
However, if the true unacceptable toxicity rate is 35% or greater, the treatment combination is not safe as 
prescribed in this protocol.  Based upon simulation studies w ith 30 subjects  using the decision rules 
described in section 15.7, the probability of terminating accrual assuming a true unacceptable toxicity rate 
of 10% and 35% is 0.039 and 0.91, respectively.  
 With the 6- month progression- free survival rate of GBM patients standardly treated after one recurrence 
being 42.6% (Friedman, JCO, 2009), we anticipate that approximately 50% of patients will drop out between enrollment and the [ADDRESS_211183] research design or data analysis (i.e. amendments affecting 
subject population, inclusion/exclusion criteria, agent administration, statistical analysis, etc.).  
 
The Principal Investigator [INVESTIGATOR_12604]- approval from the IRB within [ADDRESS_211184] enrollment.  
Pro00065241:  AVERT  
Version: [ADDRESS_211185]’s study records, and a copy of the informed consent form will be provided to the subject.  The Principal Investigator [INVESTIGATOR_12605]/her primary care physician about participation in the study.  If the subject 
agrees to such notification, the Principal Investigator [INVESTIGATOR_12606]’s primary care physician about 
the subject’s participation in the clinical study.  
16.4 Study Documentation 
 Study documentation includes but is not limited to source documents, CRFs, monitoring logs, appointment schedules, study team correspondence with sponsors or regulatory bodies/committees, and 
regulatory documents that can be found in the DCI -mandated “Regulatory Binder”, which includes but is 
not limited to signed protocol and amendments, approved and signed informed consent forms, FDA Form 
1572, CAP and CLIA laboratory certifications, and clinical supplies receipts and distribution records.  
 Source documents are original records that contain source data, which is all information in original records of clinical findings, observations, or other activities in a clinical trial necessary for the 
reconstruction  and evaluation of the trial.  Source documents include but are not limited to hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_12607], microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and records kept at the pharmacy, at the laboratories and at 
medico- techni cal departments involved in the clinical trial.  When possible, the original record should be 
retained as the source document.  However, a photocopy is acceptable provided that it is a clear, legible, and an exact duplication of the original document.  
 A CRF will be the primary data collection document for the study.  The CRFs will be updated within two 
weeks of acquisition of new source data.  Only the Principal Investigator [INVESTIGATOR_32528], research 
nurses, and investigators, are permitted to make entries, changes, or corrections in the CRF.  For paper 
CRFs, errors will be crossed out with a single line, and this line will not obscure the original entry.  Changes or corrections will be dated, initialed, and explained (if necessary).  The Principal Investigator [INVESTIGATOR_33574] a record of the changes and corrections.  For electronic CRFs, an audit trail will be maintained by [CONTACT_179507]. 
16.[ADDRESS_211186]’s data will be 
maintained. RDSPs will be approved by [CONTACT_168877].  
 To protect privacy, every reasonable effort will be made to prevent undue access to subjects during the course of the study. Prospective participants will be consented in an exam room where it is just the 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 51  
 research staff, the patient and his family, if desired. For all future visits, interactions with research staff 
(study doctor and study coordinators) regarding research activities will take place in a private exam room. 
All research related interactions with the participant will be conducted by [CONTACT_179508] y involved in the conduct of the research study.  
 To protect confidentiality, subject files in paper format will be stored in secure cabinets under lock and key accessible only by [CONTACT_16133]. Subjects will be identified only by a unique study number and subject initials. Electronic records of subject data will be maintained using a  Title 21 CFR Part 11 
Compliant  Clinical database, which is housed by [CONTACT_34572]. Access to electronic databases will be limited to 
the Principal Investigator, key personnel,  statisticians, the Radiolabeled Pharmacy personnel, and the 
PRTBTC data manager. Data stored on portable memory devices will be de- identified. The security and 
viability of the IT infrastructure will be managed by [CONTACT_33678]/or Duke Medicine.   Upon completion of the study, research records will be archived and handled per DUHS HRPP policy.  
Subject names or identifiers will not be used in reports, presentations at scientific meetings, or publications in scientific journals . 
 
16.[ADDRESS_211187] inform the IRB and all other 
applicable regulatory  agencies of such action immediately.  
16.8 Records Retention 
 
The Principal Investigator [INVESTIGATOR_12608] -related records  for the longer of a period of:  
- at least two years after the date on which a New Drug Application is approved by [CONTACT_1622] (if an 
IND is involved)  
- at least two years after formal withdrawal of the IND associated with this protocol (if an IND is 
involved)  
- at least six years after study completion (Duke policy) . 
16.[ADDRESS_211188] appointments, publicly -traded or privately -held 
equities, stock options, intellectual property, and gifts.  
 
The Duke University School of Medicine’s Research Integrity Office (RIO) reviews and manages 
research- related conflicts of interest.  The Principal Investigator [INVESTIGATOR_34511]- Investigators must report 
conflicts of interest annually and within [ADDRESS_211189] a 
documented management plan that is developed in conjunction with the Duke RIO and approved by [CONTACT_1201]/IEC.  
Pro00065241:  AVERT  
Version: [ADDRESS_211190]’s visits associated in the Duke Epic Maestro Care system with this protocol which is entered after Duke IRB approval . 
 
 
 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 53  
 17 REFERENCES 
 
1. Walker, M.D., et al., Randomized comparisons of radiotherapy and nitrosoureas for the 
treatment of malignant glioma after surgery. N Engl J Med, 1980. 303(23): p. 1323-1329. 
2. Stupp, R., et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for 
Glioblastoma. N Engl J Med, 2005. 352(10): p. 987-996. 
3. Walker, M.D., et al., Evaluation of BCNU and/or radiotherapy in the treatment of 
anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 1978. 49(3): p. 333-343. 
4. Shapi[INVESTIGATOR_2152], W.R., Therapy of adult malignant brain tumors: what have the clinical trial s 
taught us?. Semin Oncol, 1986. 13(1): p. 38-45. 
5. Salford, L.G., A. Brun, and S. Nirfalk, Ten -year survival among patients with 
supratentorial astrocytomas grade III and IV. J Neurosurg, 1988. 69(4): p. 506-509. 
6. Dinapoli, R.P., et al., Phase III comparative evaluation of PCNU and carmustine 
combined with radiation therapy for high-grade glioma. J Clin Oncol, 1993. 11(7): p. 
1316-1321. 
7. Pi[INVESTIGATOR_19323], J.D., et al., Steps towards cost-benefit analysis of regional neurosurgical care. 
Br Med J, 1990. 301(6753): p. 629-635. 
8. Ekman, M. and M. Westphal, Cost of brain tumour in Europe. Eur J Neurol, 2005. 12: p. 
45-9. 
9. Imperato, J.P., N.A. Paleologos, and N.A. Vick, Effects of treatment on long -term 
survivors with malignant astrocytomas. Ann Neurol, 1990. 28(6): p. 818-822. 
10. Hall, W.A. and O. Fodstad, Immunotoxins and central nervous system neoplasia. J 
Neurosurg, 1992. 76(1): p. 1 -12. 
11. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of immunity. Nature, 
1998. 392(6673): p. 245-52. 
12. Steinman, R.M., Dendritic cells and the control of immunity: enhancing the efficiency of 
antigen presentation. Mount Sinai Journal of Medicine, 2001. 68(3): p. 106-66. 
13. Fujii, S., et al., Analysis of a chronic myelogenous leukemia patient vaccinated with 
leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Japanese Journal of Cancer Research, 1999. 90 (10): p. 1117-29. 
14. Heiser, A., et al., Autologous dendritic cells transfected with prostate-specific antigen 
RNA stimulate CTL responses against metastatic prostate tumors. Journal of Clinical Investigation., 2002. 109(3): p. 409-17. 
15. Su, Z., et al., Immunological and clinical responses in metastatic renal cancer patients 
vaccinated with tumor RNA-transfected dendritic cells.  Cancer Research, 2003. 63(9): p. 
2127-33. 
16. Holtl, L., et al., Cellular and humoral immune responses in patients with metastatic renal 
cell carcinoma after vaccination with antigen pulsed dendritic cells. Journal of Urology, 1999. 161(3): p.  777-82. 
17. Lodge, P.A., et al., Dendritic cell -based immunotherapy of prostate cancer: immune 
monitoring of a phase II clinical trial. Cancer Research, 2000. 60 (4): p. 829-33. 
18. Lim, S.H. and R. Bailey-Wood, Idiotypic protein-pulsed dendritic cell vaccination in 
multiple myeloma.  International Journal of Cancer, 1999. 83(2): p. 215-22. 
19. Hsu, F.J., et al., Vaccination of patients with B-cell lympoma using autologous antigen-
pulsed dendritic cells. Nature Medicine, 1996. 2: p. 52-58. 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 54  
 20. Murphy, G.P., et al., Higher-dose and less frequent dendritic cell infusions with PSMA 
peptides in hormone-refractory metastatic prostate cancer patients. Prostate, 2000. 43(1): 
p. 59-62. 
21. Morse, M.A., et al., A Phase I study of active immunotherapy with carcinoembryonic 
antigen peptide (CAP- 1)-pulsed, autologous human cultured dendritic cells in patients 
with metastatic malignancies expressing carcinoembryonic antigen. Clinical Cancer Research, 1999. 5(6): p. 1331-8. 
22. Tjoa, B.A., et al., Evaluation of phase I/II c linical trials in prostate cancer with dendritic 
cells and PSMA peptides.  Prostate, 1998. 36(1): p. 39-44. 
23. Thurner, B., et al., Vaccination with mage-3A1 peptide-pulsed mature, monocyte- derived 
dendritic cells expands specific cytotoxic T cells and ind uces regression of some 
metastases in advanced stage IV melanoma. Journal of Experimental Medicine, 1999. 190(11): p. 1669-78. 
24. Schuler -Thurner, B., et al., Mage-3 and influenza-matrix peptide- specific cytotoxic T 
cells are inducible in terminal stage H LA-A2.1+ melanoma patients by [CONTACT_179509]-
derived dendritic cells.  Journal of Immunology, 2000. 165(6): p. 3492-6. 
25. Salgaller, M.L., et al., Dendritic cell-based immunotherapy of prostate cancer. Critical Reviews in Immunology, 1998. 18(1 -2): p. 109-19. 
26. Salgaller, M.L., et al., Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA- A2-specific peptides 
from prostate-specific membrane antigen (PSMA).  Prostate, 1998. 35(2): p. 144-51. 
27. Rieser, C., et al., Mature dendritic cells induce T- helper type-1-dominant immune 
responses in patients with metastatic renal cell carcinoma. Urologia Internationalis, 2000. 63(3): p. 151-9. 
28. Nestle, F.O., et al., Vaccination of melanoma patients with peptide- or tumor lysate-
pulsed dendritic cells. Nature Medicine, 1998. 4(3): p. 328-32. 
29. Murphy, G., et al., Phase I clinical trial: T -cell therapy for prostate cancer using 
autologous dendritic cells pulsed with HLA-A0201- specific peptides from  prostate-
specific membrane antigen. Prostate, 1996. 29(6): p. 371-80. 
30. Vancikova, Z. and P. Dvorak, Cytomegalovirus infection in immunocompetent and 
immunocompromised individuals --a review.  Current Drug Targets Immune Endocrine & 
Metabolic Disorders, 2001. 1(2): p. 179-87. 
31. Rafferty, K.A., Jr., Herpes viruses and cancer. Scientific American, 1973. 229(4): p. 26-
33. 
32. Kadow, J.F., A. Regueiro-Ren, and S.P. Weinheimer, The role of viruses in human 
cancer development and antiviral approaches for intervention. Current Opi[INVESTIGATOR_179467], 2002. 3(11): p. 1574-9. 
33. Harkins, L., et al., Specific localisation of human cytomegalovirus nucleic acids and 
proteins in human colorectal cancer. Lancet, 2002. 360(9345): p. 1557-63. 
34. Samanta, M., et al., High prevalence of human cytomegalovirus in prostatic 
intraepi[INVESTIGATOR_179468]. Journal of Urology, 2003. 170(3): p. 998-1002. 
35. Cobbs, C.S., et al., Human cytomegalovirus infection and expression in human malignant 
glioma. Cancer Research, 2002. 62(12): p. 3347-50. 
36. Riddell, S.R. and P.D. Greenberg, Cellular adoptive immunotherapy after bone marrow 
transplantation. Cancer Treatment & Research, 1995. 76: p. 337-69. 
Pro00065241:  AVERT  
Version: [ADDRESS_211191] cytomegalovirus in 
recipi[INVESTIGATOR_175687] T-cell clones from the donor. New 
England Journal of Medicine, 1995. 333(16): p. 1038-44. 
38. Paar, D.P. and R.B. Pollard, Immunotherapy of CMV infections. Advances in 
Experimental Medicine & Biology., 1996. 394: p. 145-51. 
39. Dazzi, F. and J.M. Goldman, Adoptive immunotherapy following allogeneic bone marrow 
transplantation. Annual Review of Medicine, 1998. 49: p. 329-40. 
40. Numazaki, K., et al., Adoptive i mmunotherapy for interstitial pneumonia associated with 
cytomegalovirus infection. Clinical Infectious Diseases, 1997. 25(5): p. 1246-7. 
41. Papadopoulos, E.B., et al., Infusions Of Donor Leukocytes To Treat Epstein- Barr Virus-
Associated Lymphoproliferative Disorders After Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1994. 330(17): p. 1185-1191. 
42. Emanuel, D.J., Uses of immunotherapy for control of human cytomegalovirus-associated 
diseases.  Transplantation Proceedings., 1991. 23([ADDRESS_211192] 3): p. 144-6. 
43. Emanuel, D.J., et al., Treatment of posttransplant lymphoproliferative disease in the 
central nervous system of a lung transplant recipi[INVESTIGATOR_179469]. Transplantation, 1997. 63 (11): p. 1691-4. 
44. Liu, Z., et a l., Epstein -Barr virus (EBV) -specific cytotoxic T lymphocytes for the 
prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Research, 2002. 159: p. 123-33. 
45. Lucas, K.G. and J.C. Barrett, Adoptive immunotherapy for E BV-associated malignancies. 
Cancer Treat Research, 1999. 101: p. 203-32. 
46. Rooney, C.M., et al., Infusion of cytotoxic T cells for the prevention and treatment of 
Epstein -Barr virus-induced lymphoma in allogeneic transplant recipi[INVESTIGATOR_840]. Blood, 1998. 
92(5): p. 1549-55. 
47. Kondo, K. and E.S. Mocarski, Cytomegalovirus latency and latency- specific 
transcription in hematopoietic progenitors. Scand J Infect Dis Suppl, 1995. 99: p. 63-7. 
48. Prosch, S., et al., Human cytomegalovirus reactivation in bone-marrow- derived 
granulocyte/monocyte progenitor cells and mature monocytes. Intervirology, 1999. 42(5 -
6): p. 308-13. 
49. Reeves, M.B., et al., Latency, chromatin remodeling, and reactivation of human 
cytomegalovirus in the dendritic cells of healthy carriers.  Proc Natl Acad Sci U S A, 
2005. 102(11): p. 4140- 5. 
50. Larsson, S., et al., Cytomegalovirus DNA can be detected in peripheral blood 
mononuclear cells from all seropositive and most seronegative healthy blood donors over time.  Transfusion, 1998. 38(3): p. 271-8. 
51. Sissons, J.G., J.H. Sinclair, and L.K. Borysiewicz, Pathogenesis of human 
cytomegalovirus disease and the kidney. Kidney Int Suppl, 1991. 35: p. S8-12. 
52. Plotkin, S.A., et al., Multicenter trial of Towne strain attenuated virus vaccine in 
seronegative renal transplant recipi[INVESTIGATOR_840]. Transplantation, 1994. 58(11): p. 1176-8. 
53. BenMohamed, L., et al., Intranasal administration of a synthetic lipopeptide without 
adjuvant induces systemic immune responses. Immunology, 2002. 106(1): p. 113-21. 
54. Pepperl -Klindworth, S., N. Frankenberg, and B. Plachter, Development of novel vaccine 
strategies against human cytomegalovirus infection based on subviral particles. Journal of Clinical Virology, 2002. [ADDRESS_211193] 2 : p. S75-85. 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 56  
 55. Britt, W., et al., Fo rmulation of an immunogenic human cytomegalovirus vaccine: 
responses in mice.  Journal of Infectious Diseases, 1995. 171(1): p. 18-25. 
56. Gonczol, E., et al., Humoral immune response to cytomegalovirus Towne vaccine strain 
and to Toledo low-passage strain. Journal of Infectious Diseases, 1989. 159(5): p. 851-9. 
57. Minamishima, Y., Immunoprophylaxis of experimental cytomegalovirus infection. 
Annales de Microbiologie (Paris), 1977. 128(3): p. 399-407. 
58. Morello, C.S., M. Ye, and D.H. Spector, Development o f a vaccine against murine 
cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, 
that provides long-term, complete protection against viral replication. Journal of Virology, 2002. 76(10): p. 4822-35. 
59. Cicin -Sain, L., et al., Vaccination of mice with bacteria carrying a cloned herpesvirus 
genome reconstituted in vivo. Journal of Virology, 2003. 77(15): p. 8249-55. 
60. Adler, S.P., et al., Guinea pig and human cytomegaloviruses do not share cross- reactive 
neutralizing epi[INVESTIGATOR_322]. Journal of Medical Virology, 1995. 47(1): p. 48-51. 
61. Adler, S.P., et al., Safety and immunogenicity of the Towne strain cytomegalovirus 
vaccine.  Pediatric Infectious Disease Journal, 1998. 17(3): p. 200-6. 
62. Sachs, G.W., R.L. Simmons, and H.H. Balfour, Jr., Cytomegalovirus vaccine: persistence 
of humoral immunity following immunization of renal transplant candidates. Vaccine, 1984. 2(3): p. 215-8. 
63. Drulak, M.W., et al., Vaccination of seropositive subjects with CHIRON CMV gB subunit 
vaccine combined with MF59 adjuvant for production of CMV immune globulin. Viral Immunology, 2000. 13(1): p. 49-56. 
64. Ohizumi, Y., et al., Human cytomegalovirus neutralizing antibody response in Japanese 
children with bone marrow transplantation. Tohoku Journal of Experimental Medicine, 1994. 174(1): p. 11-7. 
65. Hammond, D., CytoGam infusions at home. Journal of Intravenous Nursing, 1999. 22(6): 
p. 331-5. 
66. Tzakis, A.G., Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus 
immune globulin in liver and intestinal transplantation. Transplant Infectious Disease, 2001. [ADDRESS_211194] 2 : p. 35-9. 
67. Falagas, M.E., et al., Cytomegalovirus immune globulin (CMVIG) prophylaxis is 
associated with increased survival after orthotopic liver transplantation. The [LOCATION_011] Center for Liver Transplantation CMVIG Study Group. Clinical Transplantation, 1997. 11(5 Pt 1): p. 432-7. 
68. Kleihauer, A., et al., Ex vivo generation of human cytomegalovirus- specific cytotoxic T 
cells by [CONTACT_79336]-pulse d dendritic cells.  British Journal of Haematology, 2001. 113(1): p. 
231-9. 
69. Cho, H.I., et al., Generation of Cytotoxic T Lymphocytes Specific for Human 
Cytomegalovirus Using Dendritic Cells In Vitro. Journal of Immunotherapy, 2001. 24(3): p. 242-249. 
70. Raftery, M.J., et al., Dendritic cells cross -presenting viral antigens derived from 
autologous cells as a sensitive tool for visualization of human cytomegalovirus- reactive 
CD8+ T cells.  Transplantation, 2002. 73(6): p. 998-1002. 
71. Peggs, K., et al., Characterization of human cytomegalovirus peptide- specific CD8(+) T -
cell repertoire diversity following in vitro restimulation by [CONTACT_488] -pulsed dendritic cells. 
Blood, 2002. 99(1): p. 213-23. 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 57  
 72. Szmania, S., et al., Isolation and expansion of cytomegalovirus- specific cytotoxic T 
lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-
tetramers.  Blood, 2001. 98(3): p. 505-12. 
73. Morse, M.A., et al., Immunotherapy with autologous, human dendritic cells transfected 
with carcinoembryonic antigen mRNA. Cancer Investigation., 2003. 21(3): p. 341-9. 
74. Van Meirvenne, S., et al., Efficient genetic modification of murine dendritic cells by 
[CONTACT_179510]. Cancer Gene Ther, 2002. 9(9): p. 787-97. 
75. Van Tendeloo, V.F., et al., Highly efficient gene delivery by [CONTACT_179511]: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood, 2001. 98(1): p. 49-56. 
76. Ponsaerts, P., et al., Messenger RNA electroporation of human monocytes, followed by 
[CONTACT_179512], leads to highly stimulatory antigen-loaded mature dendritic cells.  J Immunol, 2002. 169(4): p. 1669-75. 
77. Ponsaerts, P., et al., m RNA-electroporated mature dendritic cells retain transgene 
expression, phenotypi[INVESTIGATOR_179470]. Leukemia, 2002. 16(7): p. 1324-30. 
78. Boczkowski, D., et al., Dendritic cells pulsed with RNA are potent antigen-presenting 
cells in vitro and in vivo. Journal of Experimental Medicine, 1996. 184(2): p. 465-472. 
79. Strobel, I., et al., Human dendritic cells transfected with either RNA or DNA encoding 
influenza matrix protein M1 differ in their ability to stimulate  cytotoxic T lymphocytes.  
Gene Therapy, 2000. 7 (23): p. 2028-35. 
80. Kim, J.J., et al., Molecular and immunological analysis of genetic prostate specific 
antigen (PSA) vaccine. Oncogene, 1998. 17 (24): p. 3125-35. 
81. Sercarz, E.E., et al., Dominance and cr ypticity of T cell antigenic determinants.  Annual 
Review of Immunology, 1993. 11: p. 729-66. 
82. Kundig, T.M., et al., On the role of antigen in maintaining cytotoxic T- cell memory.  
Proceedings of the National Academy of Sciences of the [LOCATION_002] of Am erica, 1996. 
93(18): p. 9716-23. 
83. Food and Drug Administration, H.a.H.S., Biological products; bacterial vaccines and 
toxoids; implementation of efficacy review. Final rule and final order. 2004: Federal Register. p. 255-267. 
84. Atkinson, W.L., et al., General recommendations on immunization. Recommendations of 
the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) . 2002: Centers for Disease Control and Prevention. p. 1-35. 
85. Myers, M.G., et al., Primary immunization with tetanus and diphtheria toxoids. Reaction 
rates and immunogenicity in older children and adults. JAMA, 1982. 248(19): p. 2478-2480. 
86. Mitchell, D.A., et al., Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice 
and glioblastoma patients. Nature, 2015. 
87. Curran, M.A., et al., PD -1 and CTLA-4 combination blockade expands infiltrating T cells 
and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl 
Acad Sci U S A, 2010. 107(9): p. 4275-80. 
88. Squibb, B.-M., Investigator Brochure Nivolumab. 2014(Version 13). 
Pro00065241:  AVERT  
Version: [ADDRESS_211195] syngeneic intracerebral glioma. Journal of 
Neuroimmunology, 2000. 103(1): p. 16-25. 
90. Ashley, D.M., et al., Bone marrow- generated dendritic cells pulsed with tumor extracts 
or tumor RNA induce antitumor immunity against central nervous system tumors. Journal of Experimental Medicine, 1997. 186(7): p. 1177-1182. 
91. Liau, L., e t al., Treatment of intracranial gliomas with bone marrow-derived dendritic 
cells pulsed with tumor antigens. Journal of Neurosurgery, 1999. 90(6): p. 1115-1124. 
92. Heimberger, A.B., et al., Dendritic cells pulsed with a tumor- specific peptide induce 
long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery, 2002. 50: p. 158-166. 
93. Bodmer, S., et al., Immunosuppression and transforming growth factor-beta in 
glioblastoma. Preferential production of transforming growth factor-beta 2. Journal of Immunology, 1989. 143(10): p. 3222-3229. 
94. Kuppner, M.C., et al., The glioblastoma- derived T -cell suppressor factor/transforming 
growth factor beta 2 inhibits the generation of lymphokine- activated killer (LAK) cells.  
International Journal Cancer, 1988. 42(4): p. 562-567. 
95. Maxwell, M., et al., Effect of the expression of transforming growth factor-beta 2 in 
primary human glioblastomas on immunosuppression and loss of immune surveillance. J.Neurosurg., 1992. 76(5): p. 799-804. 
96. Wahl, S.M., et al., Transforming growth factor-beta is a potent immunosuppressive agent 
that inhibits IL -1-dependent lymphocyte proliferation. Journal of Immunology, 1988. 
140(9): p. 3026-3032. 
97. Zuber, P., M.C. Kuppner, and N. de Tribolet, Transform ing growth factor-beta [ADDRESS_211196] antigen expression on human malignant glioma cells. European Journal of Immunology, 1988. 18(10): p. 1623-1626. 
98. Kikuchi, T., et al., Vaccination of glioma patients with fusions of dendritic and glioma 
cells and recombinant human interleukin 12. Journal of Immunotherapy with Emphasis 
on Tumor Immunology, 2004. 27: p. 452-9. 
99. Westphal, M., et al., A phase 3 trial of local chemotherapy with biodegradable 
carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro -oncology, 2003. 5 : p. 79-88. 
100. Boskovitz, A., et al., Monoclonal antibodies for brain tumour treatment. Expert Opi[INVESTIGATOR_179471] 2004. 4(9): p. 1453-71, [ADDRESS_211197] a diminished CD4 
compartment explains cellular immune defects in patients with malignant glioma. Cancer Research, 2006. 66(6): p. 3294-302. 
102. El Andaloussi, A., Y. Han, and M.S. Lesniak, Prolongation of survival following 
depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg, 2006. 105(3): p. 430-7. 
103. Heimberger, A.B., Crotty, L.E., Archer, G.E., Hess, K.R., Wikstrand, C.J., Friedman, 
A.H., Friedman, H.S., Bigner, D.D., Sampson, J.H., Epi[INVESTIGATOR_179472]. Clinical Cancer Research., 2003. 9: p. 4247-4254. 
104. Phan, G.Q., et al., Cancer regression and autoimmunity induced by [CONTACT_28746] T 
lymphocyte -associated antigen 4 blockade in patients with metastatic melanoma. 
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 59  
 Proceedings of the National Academy of Sciences of the [LOCATION_002] of America, 2003. 
100(14): p. 8372-7. 
105. Attia, P., et al., Autoimmunity correlates with tumor regression in patients with 
metastatic melanoma treated with anti- cytotoxic T -lymphocyte antigen- 4.[see comment].  
Journal of Clinical Oncology, 2005. 23(25): p. 6043-53. 
106. Jaber, S.H., et al., Skin reactions in a subset of patients with stage IV melanoma treated 
with a nti-cytotoxic T -lymphocyte antigen 4 monoclonal antibody as a single agent. 
Archives of Dermatology, 2006. 142(2): p. 166-72. 
107. Blansfield, J.A., et al., Cytotoxic T -lymphocyte-associated antigen-4 blockage can induce 
autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy, 2005. 28(6): p. 593-8. 
108. Homma, S., et al., Cancer immunotherapy using dendritic/tumour-fusion vaccine induces 
elevation of serum anti-nuclear antibody with better clinical responses. Clinical & Experimental Immunology, 2006. 144(1): p. 41- 7. 
109. Wolchok, J.D., et al., Guidelines for the evaluation of immune therapy activity in solid 
tumors: immune- related response criteria.  Clin Cancer Res, 2009. 15(23): p. 7412-20. 
110. Wen, P.Y., et al., Updated response assessment criteria for high-grade gliomas: response 
assessment in neuro-oncology working group. J Clin Oncol, 2010. 28(11): p. 1963-72. 
111. Wolchok, J.D., et al., Nivolumab plus ipi[INVESTIGATOR_15172]. N Engl J Med, 
2013. 369(2): p. 122-33. 
112. Topalian, S.L., et al., Safety, activity and immune correlates of anti-PD1 antibody in 
cancer. N Engl J Med, 2012. 366(26): p.2443-54. 
 
  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 60  
 18 APPENDICES 
 
18.1 Nivolumab Investigator Brochure (s) 
Please see separate upload in eIRB.  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 61  
 18.2 I-O Safety Algorithms  
Please see separate upload in eIRB.   
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 62  
 18.3 PRTBTC Imaging SOP  
Please see separate upload in eIRB.  
 
  
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 63  
  
18.4 CTRAF 
Please see separate upload in eIRB.   
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 64  
 18.5 MMSE 
Please see separate upload in eIRB.   
Pro00065241:  AVERT  
Version: [ZIP_CODE] 315 
 
Duke Cancer Institute  CONFIDENTIAL  Page 65  
 18.6 PRTBTC DSMBplus Charter 
Please see separate upload in eI RB. 